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Abstract 
The amplification of the MYCN oncogene, occurring in 20% of neuroblastomas, a 
tumor of early childhood, is associated with drug-resistant relapse and poor 
prognosis. High MYCN expression has paradoxical effects in most cells: it promotes 
cell cycle progression and sensitizes to cell death. This work aims to characterize, at 
population and single-cell level, the mechanisms through which amplified MYCN 
allows tumor regrowth after chemotherapy in neuroblastoma. 
In MYCN-regulatable neuroblastoma cell line models, MYCN shortens the lengths of 
cell cycle phases, preferentially in G1, and increases the proportion of cycling cells 
under exponential growth. Upon DNA-damage induced by the chemotherapeutic 
agent, doxorubicin (DOX), MYCN delays activation of cell cycle checkpoints and 
boosts the proportion of transiting cells. During and after chemotherapy MYCN favors 
cell death and suppresses cellular senescence, shifting p53 downstream effects from 
cell cycle arrest to apoptosis. However, MYCN also drives clonal regrowth of a small 
fraction of surviving resister cells after DNA-damage. These resister cells exhibit 
nearly identical molecular and phenotypic profiles as cells before treatment. Live-cell 
imaging reveals that resister cells arise exclusively from the G1-phase-arrested 
subpopulation and rapidly repair DNA-damage-induced double-strand breaks 
(DSBs). The suppression of DNA repair via ATM inhibition during chemotherapy 
results in reduction of G1 phase arrest and prevents DNA DSB repair, completely 
eradicating resister cells. 
Taken together, these data show that non-genetic tumor heterogeneity and a key 
oncogenic lesion, MYCN, synergize to resume cellular proliferation after DNA 
damage and probably cause chemotherapy resistance. This work indicates that 
improved first-line therapies could specifically target resister cells and help avoid 
cellular regrowth.  
IV 
Zusammenfassung 
Die Amplifikation des Onkogens MYCN tritt in 20% der Neuroblastome auf und ist mit 
therapieresistenten Rezidiven sowie einer schlechten Prognose assoziiert. Die 
Expression von MYCN hat paradoxale Effekte in den meisten Zellen: sie fördert die 
Zellzyklusprogression und sensibilisiert zum Zelltod. Diese Arbeit hat zum Ziel, die 
Mechanismen, durch welche die MYCN-Amplifikation erneutes Tumorwachstum 
nach einer Chemotherapie ermöglicht, zu charakterisieren. Dies erfolgt sowohl auf 
Populations- als auch auf Einzelzellebene.  
Im Rahmen dieser Arbeit wurde gezeigt, dass in MYCN-regulierbaren 
Neuroblastomzelllinien MYCN die Länge der Zellzyklusphasen verkürzt, 
vorzugsweise in G1, und den Anteil von zyklierenden Zellen bei exponentiellem 
Wachstum erhöht. Bei durch das Chemotherapeutikum Doxorubicin (DOX) 
induzierten DNA-Schäden verzögert MYCN die Aktivierung von Zellzyklus-
Checkpoints und erhöht den Anteil der Zellzyklus-durchlaufenden Zellen. Während 
und nach der Chemotherapie begünstigt MYCN den Zelltod und unterdrückt zelluläre 
Seneszenz. Dies erfolgt durch Verschieben der p53-nachgeschalteten Effekte von 
Zellzyklusarrest zu Apoptose. Allerdings treibt MYCN nach der Chemotherapie auch 
das klonale Wachstum eines kleinen Anteils von überlebenden resistenten Zellen. 
Diese resistenten Zellen weisen fast identische molekulare und phänotypische Profile 
auf wie die Zellen vor der Behandlung. Live-Cell-Imaging zeigt, dass resistente 
Zellen ausschließlich aus der in der G1-Phase-arrestierten Sub-population 
entstehen. Diese Zellen reparieren zudem schnell die durch DNA-Schäden 
hervorgerufenen DNA-Doppelstrangbrüche (DSB). Eine Unterdrückung der DNA-
Reparatur während der Chemotherapie über eine ATM-Hemmung bewirkt die 
Reduktion des Arrests in der G1-Phase und verhindert die DNA-DSB Reparatur. Dies 
führt zur kompletten Ausrottung von resistenten Zellen. 
Die Ergebnisse dieser Arbeit zeigen, dass nichtgenetische Tumorheterogenitäten 
und die onkogene Läsion MYCN, synergieren, um die Wiederaufnahme zellulärer 
Proliferation im Anschluss an eine Beschädigung der DNA zu starten und somit zu 
Chemotherapieresistenz führen können. Außerdem wurde gezeigt, dass eine 
verbesserte Ersttherapie spezifisch auf resistente Zellen zielen könnte, um so 
erneutes Zellwachstum zu verhindern. 
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1. Introduction 
1.1. Clinical aspects of neuroblastoma 
Neuroblastoma is the most common extra cranial solid tumor in children, 
accounting for 8-10% of childhood cancers in the USA and Europe (Gatta et al., 
2014; Maris et al., 2007; Smith et al., 2010). About 37% of the cases are diagnosed 
as infants, and 90% are younger than 5 years at diagnosis, with a median age at 
diagnosis of 19 months (London et al., 2005). Neuroblastoma originates from 
neural crest derived cells, which migrate away from the neural tube early during 
embryogenesis (Betters et al., 2010). The tumors can affect the whole sympathetic 
nervous system with a preference to arise in the adrenal medulla (Westermann and 
Schwab, 2002). The clinical behavior of neuroblastoma is very heterogeneous 
varying from spontaneous regression to cases of highly aggressive metastatic 
disease unresponsive to any anti-cancer treatment. The high frequency of 
spontaneous regression, 10 to 100 fold higher compared to all other tumors, is an 
unique feature of neuroblastoma (Pritchard and Hickman, 1994).  
The age of diagnosis is an important predictive factor for clinical outcome. Infants 
younger than 1.5 year have a good prognosis for survival, while older patients have 
adverse prognosis, and in adult and adolescent patients neuroblastoma is 
ultimately fatal in most cases (Franks et al., 1997; London et al., 2005; Schmidt et 
al., 2005; Westermann and Schwab, 2002). 
The International Neuroblastoma Risk Group Staging System (INRGSS) is used to 
classify the tumors into stages. This system is based on clinical criteria and image-
defined risk factors at the time of diagnosis (Table 1). The INRGSS divides stages 
into L1, L2, M or MS. In general, patients with low risk disease (L1) have 90% event 
free survival rates with observation only or minimal therapeutic interventions 
(Monclair et al., 2009). Patients with intermediate risk disease have event free 
survival of 78% and usually undergo surgery and chemotherapy. Currently, many 
groups are focused on using biological markers to help to decrease therapy in 
specific subpopulations of children (Louis and Shohet, 2015; Park et al., 2013).  
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 Table 1. International neuroblastoma risk group (INRG) staging system (Monclair et al., 
2009). 
Stage Definition 
L1 Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment 
L2 Locoregional tumor with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months with metastases confined to skin, liver/or bone marrow. 
Patients with high-risk disease (M), which account approximately half of all new 
neuroblastoma cases each year, require treatment with multi-modal therapy using 
chemotherapy, surgery, radiotherapy high-dose chemotherapy with autologous 
stem cell rescue and biologic and immunotherapeutic maintenance therapy in order 
to improve their survival rates (Louis and Shohet, 2015). However, despite these 
extremely high cytotoxic therapies, children with high-risk neuroblastoma still have 
survival rates <40% (Kreissman et al., 2013; Kushner et al., 2004; Maris, 2010; 
Sorkin et al., 2010). Approximately 10% of children have a special form of 
metastatic disease, characterized as stage MS (metastasis special). This stage is 
clinically defined by the age of diagnosis (younger than 18 months) and restriction 
of distant metastases to skin, liver and/or bone marrow (Oberthuer et al., 2009). A 
high percentage of stage MS patients are expected to undergo spontaneous 
regression (Maris, 2010), although some children need treatment due to life-
threatening initial symptoms or may succumb to disease following rapid tumor 
growth (Oberthuer et al., 2009). 
As a big number of children will still relapse and eventually die from the disease, 
the aim for investigators is to better understand the origin of the disease and to 
develop novel treatment strategies for those who are diagnosed with high-risk 
neuroblastoma. 
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1.2. Genetic factors in development of neuroblastoma 
1.2.1. Genetics of hereditary neuroblastoma 
Familiar neuroblastoma concerns only approximately 1% of all cases (Shojaei-
Brosseau et al., 2004). Neuroblastoma pedigrees show an autosomal dominant role 
of inheritance with incomplete penetrance. Constitutional activating anaphase 
lymphoma kinase (ALK) mutations, on chromosome 2p23, have been identified in 
more than half of all familiar cases (Janoueix-Lerosey et al., 2008; Mosse et al., 
2008). ALK is an orphan receptor tyrosine kinase that acts as a major oncogenic 
driver in different human malignancies, including anaplastic large cell lymphoma 
and non-small cell lung carcinoma (Bosse and Maris, 2015; Carpenter and Mosse, 
2012). In familiar neuroblastoma, constitutive ALK activation occurs through kinase 
domain mutations, and often identical activating mutations also have been found in 
sporadic neuroblastoma tumors (Bosse and Maris, 2015; Bresler et al., 2014; 
Carpenter and Mosse, 2012; George et al., 2008; Mosse et al., 2008). 
Approximately 10% of familiar neuroblastomas are associated with two neural crest 
derived congenital anomalies: Hirschsprung’s disease, characterized with an 
aganglionic distal section of bowel, and Ondine’s Curse, also called 
congentialcentral hypoventilation syndrome (CCHS). Majority of children with these 
diseases have mutations in the paired-like homeobox 2B (PHOX2B) gene on 
chromosome 4p12 that encodes a transcription factor integral to neural crest 
development, loss of which disrupts terminal differentiation of neuroblastoma cells 
(Amiel et al., 2003; Mosse et al., 2013). 
The cause of the remaining cases of familiar neuroblastoma that do not harbor 
obvious ALK and PHOX2B mutations is currently under investigation.  
 
1.2.2. Somatic genetic alterations in neuroblastoma 
Approximately 66% of neuroblastoma tumors are hyperdiploid or near-triploid DNA 
content (Cohn et al., 2009; George et al., 2005; Look et al., 1991). These tumors 
usually have gains of whole chromosomes and low frequency of chromosomal 
rearrangements and associated with lower risk of diseases and favorable clinical 
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outcomes (Maris, 2005; Westermann and Schwab, 2002). In contrast, the majority 
of aggressive neuroblastoma tumors have either near-diploid or near-tetraploide 
DNA content (Bosse and Maris, 2015; Janoueix-Lerosey et al., 2009; 
Schleiermacher et al., 2012). They are characterized by high degree of 
chromosomal rearrangements, such as amplification, deletions and unbalanced 
translocations (Cohn et al., 2009; George et al., 2005; Look et al., 1991).  
 
Figure 1. Model for neuroblastoma pathogenesis based on recurrent genomic alterations. 
Adapted from (Peifer et al., 2015). 3n – near triploid, 2n – near diploid, LR – low risk, HR – high risk, 
MNA – MYCN-amplified.  
To date, the most aggressive tumors are defined by three major genomics 
alterations: TERT (telomerase reverse transcriptase) rearrangement, MYCN 
amplification and ATRX (a-thalassemia/mental retardation syndrome X-linked) 
mutations (Brodeur et al., 1984; Peifer et al., 2015). These alterations occur only in 
high-risk neuroblastomas in a mutually exclusive fashion (Peifer et al., 2015). 
Recurrent genomic rearrangements affecting a chromosomal region at 5p15.33 
proximal of the TERT gene has been recently discovered by the whole genome 
sequencing study in approximately one-quarter of high-risk neuroblastomas (Peifer 
et al., 2015). The 5p15.33 rearrangements juxtapose the TERT coding sequence to 
strong enhancer elements, which results in a massive chromatin remodeling and 
DNA methylation of the affected regions (Peifer et al., 2015). Not only TERT 
rearrangements but also elevated TETR expression were found to be associated 
with aggressive neuroblastomas (Peifer et al., 2015). 
Amplification of the MYCN oncogene at chromosome 2p24 is the classic genetic 
aberration of neuroblastoma consistently associated with poor outcome (Brodeur et 
3n
2n 2n/4n
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al., 1984; Seeger et al., 1985). MYCN amplification develops in approximately 20% 
of all primary neuroblastoma tumors and in 50% of high-risk tumors and strongly 
correlates with aggressive advanced-stage disease and treatment failure (Brodeur 
et al., 1984; Seeger et al., 1985).  
Inactivating ATRX mutations have been identified in more than 10% of 
neuroblastomas enriched in older children (Cheung et al., 2012; Molenaar et al., 
2012b; Pugh et al., 2013). Mutations of ATRX are associated with increase in 
telomere lengths and with absence of the ATRX protein in the nucleus (Heaphy et 
al., 2011; Kurihara et al., 2014). 
In general, pediatric tumors have a much lower frequency of somatic mutations 
than most adult cancers (Vogelstein et al., 2013). Recent genomic sequencing 
efforts discovered only few additional recurrent somatic mutations in neuroblastoma 
tumors at the time of diagnosis, Table 2. Activating mutations of ALK tyrosine 
kinase receptor occur in 8-10% of all sporadic neuroblastomas. ARID1B and 
ARID1A, chromatin remodeling proteins, are also frequently mutated in 
neuroblastoma and represent a significant subset of clinically aggressive 
neuroblastomas (Sausen et al., 2013). Mutations in RAS/MAPK pathway are rare in 
primary neuroblatoma but recently have been more frequently found in relapsed 
tumors (Eleveld et al., 2015; Pugh et al., 2013). Chromothripsis has been described 
to occur in 18% of high-risk neuroblastomas (Molenaar et al., 2012b). 
The activity of CyclinD1/CDK4/CDK6/Rb cell cycle regulatory pathway correlates 
with MYCN amplification and provide a biological marker for potentially susceptible 
patients (Carr-Wilkinson et al., 2010; Gogolin et al., 2013; Molenaar et al., 2003; 
Rader et al., 2013). The somatic activating mutations in this pathway are rare, 
however genomic amplifications of CCND1 and CDK4 or deletion of CDKN2A 
identified to increase CDK4/6 expression and kinase activity through this drive cell 
cycle progression (Caren et al., 2008; Krasnoselsky et al., 2005; Molenaar et al., 
2012a; Molenaar et al., 2003; Pugh et al., 2013). The frequency of these 
aberrations may be higher in the relapsed neuroblastomas (Carr-Wilkinson et al., 
2010; Eleveld et al., 2015).  
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Table 2: Potentially actionable genomic alterations in neuroblastoma. Rare indicates <5% 
prevalence. Modified from and adapted from (Bosse and Maris, 2015). 
Clinically Actionable 
pathway/Gene 
Prevalence 
at diagnosis 
Prevalence 
at relapse 
References 
Telomerase dysfunction 
TERT rearrangements 21%  (Peifer et al., 2015) 
MYCN amplification 16%-38%  (Brodeur et al., 1984; Seeger et al., 1985) 
ATRX 
deletion/mutation 
9%-22% 17% (Cheung et al., 2012; Eleveld et al., 2015; 
Pugh et al., 2013) 
ALK 
Mutation/amplification 8%-10% 26%-43% (Cheung et al., 2012; Eleveld et al., 2015; 
Molenaar et al., 2012a; Pugh et al., 2013; 
Sausen et al., 2013; Schleiermacher et al., 
2014; Shukla et al., 2012) 
Cell cycle control 
CDK4/6 amplification 4% - (Molenaar et al., 2012a) 
Cyclin D1 
amplification 
2%-15% - (Molenaar et al., 2003) 
CDKN2A deletion 0%-20% 13%-22% (Carr-Wilkinson et al., 2010; Meijering et al., 
2012; Omura-Minamisawa et al., 2001) 
DNA damage pathway 
TP53 1%-8%  15% (Carr-Wilkinson et al., 2010; Omura-
Minamisawa et al., 2001; Pugh et al., 2013) 
MDM2 amplification 13% 13% (Carr-Wilkinson et al., 2010) 
Chromatin modification 
ARID1A/ARID1B 
deletion/mutation 
11% Rare (Eleveld et al., 2015; Sausen et al., 2013) 
RAS-MAPK pathways 
NRAS, KRAS, HRAS, 
NF1, BRAF, PTPN11, 
FGFR1 
Rare Rare (Eleveld et al., 2015; Pugh et al., 2013; 
Shukla et al., 2012) 
Allelic losses at chromosome 1p and chromosome 11q also carry prognostic 
information in neuroblastoma. The deletion at 1p36 and loss of chromosome 11q 
occur in up to 35% and 33% of primary neuroblastomas respectively. They are 
markers for poor prognosis and associated with high-risk clinical and genomic 
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features, such as MYCN amplification, older age and metastatic disease (Attiyeh et 
al., 2005; Caron et al., 1993; Maris et al., 2000; White et al., 2001). 
 
1.3. MYC proteins in normal development 
In 1983 Schwab and his colleagues first brought the attention to MYCN as a 
putative oncogene (Kohl et al., 1983; Schwab et al., 1983). It showed that a subset 
of human neuroblastoma cells lines harbor multiple copies of a DNA sequence 
related to the MYCC oncogene and this region was named MYCN. 
MYCN belongs to the MYC family of basic-helix-loop-helix-leucine zipper (bHLH-
LZ) transcription factors, which are proto-oncogenes (Henriksson and Luscher, 
1996). The MYC family also includes MYCC and MYCL. The MYC proteins consist 
of an amino-terminal transcriptional activation domain and a carboxy-termintal 
DNA-binding and protein interaction domain. MYCC and MYCN proteins both 
heterodimerize with MAX at consensus E-box sequences (CANNTG), which is 
required for direct binding of MYC proteins to DNA (Meyer and Penn, 2008). 
Whereas MAX is stable and constantly expressed, MYC family members have 
short half-lives and their expression is highly regulated (Grandori et al., 2000).  
The MYC proteins induce a vast number of targets including genes involved in 
proliferation and cell cycle promotion, metabolism, protein synthesis, mitochondrial 
biogenesis and function (Dang et al., 2006; Sabo et al., 2014). MYC can also 
repress gene expression by binding to transcription factors Miz-1 and SP-1 and 
through this inhibit transcription of their downstream targets (Adhikary and Eilers, 
2005). This way MYC can repress many negative cell cycle regulators and genes 
involved in cell adhesion (Seoane et al., 2002).  
Although biochemical properties for MYCC and MYCN are very similar, they are 
separately regulated. While MYCC expression is more generalized, MYCN has a 
restricted expression pattern. MYCC is highly expressed in most rapidly 
proliferating cells during development and in the adult (Zimmerman et al., 1986). 
MYCN expressed during embryo development in pre-B cells, brain, kidney, lung 
and heart (Stanton et al., 1992; Zimmerman et al., 1986). After embryonic 
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development MYCN is downregulated and not significantly expressed in adult 
tissue. 
MYCN plays a profound role during embryonic development. MYCN promotes 
proliferation of granule neuron precursors derived from neuronal progenitor cells of 
the developing forebrain and hindbrain (Beltran, 2014; Knoepfler et al., 2002). 
Mutations or constitutive deletions of MYCN gene are embryonic lethal whereas 
conditional inactivation of MYCN in neuronal progenitor cells leads to ataxia, 
behavior abnormalities and tremors (Charron et al., 1992; Stanton et al., 1992).  
These developing defects correlate with 2-fold decrease in brain mass that 
disproportionally affects the cerebellum and the cerebral cortex, both of which show 
features of disorganization. The analysis of cells revealed that the cell proliferation 
is compromised through decrease of S phase and mitotic cells, whereas apoptosis 
is unaffected (Charron et al., 1992; Stanton et al., 1992). Enhanced expression of 
MYCN in the neural crest enables proliferation of immature neuronal precursor cells 
and suppresses differentiation (Swartling et al., 2012). 
 
1.4. MYCN oncoprotein in different cancer types 
Amplification and/or overexpression of MYCN is not only the feature of 
neuroblastoma, but also has been found in various other tumor types, cf. Table3.  
In general the presence of MYCN alteration had been associated with poor 
prognosis and tumor aggressiveness suggesting a similar driving role in MYCN- 
amplified and/or overexpressing tumors (Beltran, 2014). 
Table 3. MYCN amplified tumors. Modified from Beltran et al., 2014.  
Tumor type Frequency of MYCN 
alteration 
Clinical amplification References 
Neuroblastoma Amplification in 20% Poor prognosis, selection 
for aggressive treatment 
(Brodeur et al., 1984; 
Look et al., 1991; 
Schneiderman et al., 
2008; Seeger et al., 
1985) 
Medulloblastoma Amplification in 5% Poor prognosis (Aldosari et al., 2002; 
Swartling et al., 
2010) 
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Glioblastoma 
multiforme 
Overexpression in a 
subset 
Histone 3.3 mutations 
associated with 
overexpression of MYCN 
(Bjerke et al., 2013; 
Hodgson et al., 
2009) 
Retinoblastoma Amplification in < 5% Poor prognosis, early 
onset, unilateral 
nonhereditary 
(Lee et al., 1984; 
Rushlow et al., 2013) 
Alveolar 
rhabdomyosarcoma 
Amplification in 25% 
Overexpression in 
55% 
Poor prognosis, correlates 
with presence of PAX3-
FOXO1 or PAX7-FAXO1 
fusion genes 
(Tonelli et al., 2012) 
Small-cell lung 
cancer 
Amplification in 15%-
20% 
Poor response to 
chemotherapy, shorter 
survival 
(Beltran, 2014; Funa 
et al., 1987; Nau et 
al., 1986)  
Prostate cancer Amplification in 40% 
of neuroendocrine 
prostate cancer, 5% 
of prostate 
adenocarcinoma 
Clinical aggressiveness (Beltran et al., 2011; 
Mizukami et al., 
1995; Mosquera et 
al., 2013)  
Breast cancer Overexpression in a 
subset 
Correlates with poor 
prognostic features 
(Mizukami et al., 
1995) 
 
1.5. Cell cycle regulation and MYCN 
The cell cycle has four sequential phases: G1, S, G2, M (Figure 2A) .The most 
important phases are S phase, when DNA replicates, and M phase, when one cell 
divides into two daughter cells. G1 is the gap after mitosis where the cell has 2n 
chromosomes. At this time the cell is sensitive to positive and negative factors from 
the growth signaling network, (Williams and Stoeber, 2012). G2 phase follows the 
from S phase, cell has already 4n DNA content and prepares for the entry into 
mitosis (Murray, 1993). G0 is a state during G1 phase when cells have reversibly 
withdrawn from the cell division cycle in response to high cell density or mitogen 
deprivation (Zimmerman et al., 1986). Cells can also be irreversibly withdrawn from 
the cell cycle into terminally differentiated or senescence states (Hall and Watt, 
1989; Williams and Stoeber, 2012). Progression through the cell cycle phases is 
under the control of a family of serine/threonine protein kinases. These kinases are 
heterodimers consisting of a catalytic subunit, the cyclin dependent kinase (CDK) 
and their regulatory partners the cyclins (Malumbres and Barbacid, 2006). To date, 
21 genes encoding CDKs and 29 genes encoding cyclins are identified in the 
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human genome (Malumbres and Barbacid, 2005; Malumbres et al., 2009) CDK4/6-
cyclin D and CDK2-cyclin E drive G1 progression through the restriction point, 
which afford the cell to complete the cell cycle. CDK2-cyclin A initiates S phase, 
and CDK1-cyclin B regulates progression through G2 and entry into mitosis. The 
activation of G1 phase CDKs leads to the phosphorylation and inactivation of 
retinoblastoma protein (Rb). The inactivated Rb protein is released from its complex 
with E2F family of transcription factors and the reaction promotes G1/S transition, 
Figure 2B (Dyson, 1998; Friend et al., 1986; Nevins, 2001). 
 
Figure 2. Cell cycle phases in mammalian cell cycle.  
Progression and transition through each cell cycle phase are monitored by sensor 
mechanisms, called checkpoints, which maintain the correct order of events 
(Hartwell and Weinert, 1989). If the sensor mechanisms detect aberrant of 
incomplete cell cycle (i.e. DNA damage), checkpoints pathway can carry the signals 
to effectors that trigger cell cycle arrest until the problem is resolved (Bartek et al., 
2004; Musacchio and Salmon, 2007). Effector proteins include the CDK inhibitors 
(CDKIs), which can reversibly trigger cell cycle arrest. Based on sequence and 
structure similarity, CDKIs consist of two protein families: the INK4 (inhibitors of 
CDK4), and the CIP/KIP (CDK Interacting Protein/Kinase inhibitory Protein) families 
(Pavletich, 1999; Sherr and Roberts, 1999). The INK4 family consists of p16INK4A, 
p15INK4B, p18INK4C, p19INK4, which inhibit CDK4 and CDK6 and arresting the cell 
cycle in G1-phase (Pavletich, 1999; Sherr and Roberts, 1999). The CIP/KIP family 
includes three members: p21CIP1 (CDK Interacting Protein1, later p21), P27KIP1 
(Kinase Inhibitory Protein1), and p57KIP2 (Kinase Inhibitory Protein 2), which inhibit 
CDK2 and CDK1 activity and can induce cell cycle arrest at every cell cycle phase 
(Malumbres et al., 2009). 
M
S
G1G2
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The best characterized tumorigenic effect of MYC proteins is to promote 
proliferation and cell cycle progression (Huang and Weiss, 2013). The influence of 
ectopic MYCN expression on the cell cycle was first investigated using TET21N 
system (Lutz et al., 1996). Similar to MYCC, MYCN over-expression induces the re-
entry of quiescent cells into the cell cycle, shortens the time of cell cycle 
progression, in particular shortens the G1 phase and decreases cell attachment to 
the extracellular matrix (Bell et al., 2010; Lutz et al., 1996). Conversely, the 
reduction of MYCN expression by MYCN siRNA was found to cause cell cycle 
arrest (Bell et al., 2010). 
 
1.6. p53 pathway in neuroblastoma 
The p53 tumor suppressor pathway has been described as the “guardian of the 
genome” (Lane, 1992). Therefore the inactivation of this pathway is the hallmark of 
cancer and occurs in approximately 50% of all human tumors, which harbor 
inactivating mutations of the TP53 gene (Hanahan and Weinberg, 2011). The p53 
protein is a transcription factor, which due to its short half-life, is present at very low 
levels in the cell under normal physiological conditions (Honda et al., 1997). Upon 
different types of cellular stresses, e.g. DNA damage, p53 protein is rapidly 
phosphorylated on serine 15 and 20 by the ATM and CHK2 kinases, respectively, 
which leads to stabilization and activation of the p53 (Banin et al., 1998; Shieh et 
al., 2000). An important negative regulator of p53 is MDM2. This protein represses 
p53 mediated transactivation, targets p53 for proteasomal degradation and is 
transcriptionally activated by p53, thus executing a negative feedback on p53 
(Marine et al., 2006; Oliner et al., 1993; Sherr, 1998; Thut et al., 1997). MDM2 is 
controlled by p14ARF, which binds MDM2 directly and prevents the MDM2 mediated 
p53 degradation, leading to stabilization and activation of p53.  
Active p53 induces expression of genes responsible for cell cycle arrest (CDKN1A, 
14-3-3 sigma, GADD45) or apoptosis induction PUMA, BAX (Crescenzi et al., 
2008). Additionally p53 is known for triggering different types of senescence, 
including replicative senescence (seen in aging human fibroblasts) and drug-
induced senescence. Senescence is a non-reversible, terminal cell cycle exit, 
characterized by enlarged nuclei, flattened cell morphology presence of β-
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Galactosidase activity at suboptimal conditions (by pH 6), and albescence of cell 
division in metabolically active cells (Noda et al., 1994). Although, the exact 
molecular pathways underlying the process of senescence remain to be elucidated, 
several studies have shown that senescence is highly associated with a sustained 
upregulation of the p21 protein (Mirzayans et al., 2012; Shay, 1999). 
Interestingly, p53 is rarely mutated in neuroblastoma. The frequency of p53 
mutations in tumors at diagnosis is less than 2% (Tweddle et al., 2003). After tumor 
relapse or progression p53 still stays active in more than 85% of tumors (Carr-
Wilkinson et al., 2010). The defects in the upstream regulators of p53 (MDM2 
amplification and p14ARF deletion or methylation) are present in the primary and 
relapse tumor with the same proportion (Carr-Wilkinson et al., 2010).  
  
1.7. MYCN-induced apoptosis and deregulation of p53 pathway 
Most MYCN-amplified neuroblastomas initially respond well to chemotherapy but 
the tumors frequently relapse. Members of MYC family, including MYCN, are 
known to play a dual role in driving proliferation by up and down regulation of cell 
cycle genes and sensitizing cells to apoptosis. This paradox is observed historically 
in human MYCN amplified neuroblastoma tumors and TH-MYCN transgenic mouse 
neuroblastoma tumors (Altungoz et al., 2007; Goto et al., 2001; Moore et al., 2008; 
Shimada et al., 1999; Shimada et al., 1995). 
TP53 is known to be a direct target gene of MYCC and mediates MYCC induced 
apoptosis (Reisman et al., 1993; Roy et al., 1994; Zeller et al., 2003). Several 
studies in neuroblastoma demonstrated that MYCN amplified tumors and cell lines 
express significantly high levels of p53 mRNA, p53 protein and several p53 target 
genes in comparison with non-amplified tumors and cell lines (Bell et al., 2006; 
Chen et al., 2010; Cui et al., 2005; Westermann et al., 2008). It has been shown 
that MYCN promotes p53 accumulation by interacting directly with the same E-Box 
motif (CATGTG) as previously found for MYCC (Chen et al., 2010; Reisman et al., 
1993). Works from different labs suggest that these functional interactions between 
MYCN and p53 represent an important and direct mechanism by which MYCN 
sensitizes cells to apoptosis (Chen et al., 2010). These findings can explain why 
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human MYCN amplified and TH-MYCN transgenic mouse neuroblastoma tumors 
have high levels of apoptosis and MYCN amplified and MYCN overexpressing 
neuroblastoma cells undergo higher levels of apoptosis after treatment with 
chemotherapeutic drugs and with irradiation (Bell et al., 2006; Chesler et al., 2008; 
Fulda et al., 2000; Paffhausen et al., 2007). 
Interestingly, MYCN promotes transcription of p53 negative regulator MDM2, 
through direct transcriptional activation, and through activation of TP53, as MDM2 
is a target for p53-mediated transcription (Chen et al., 2010; Slack et al., 2005). 
Another important way through that MYCN impairs p53 signaling is inhibition of p21 
gene expression (Bell et al., 2006). Activation of p21 after DNA damage is required 
for cell cycle arrest and senescence. MYCN amplification is significantly associated 
with low level of p21 induction and failed G1 arrest after ionizing irradiation in p53 
wild type neuroblastoma cell lines (Bell et al., 2006; Tweddle et al., 2001). It has 
been reported that MYCC suppresses p21 expression by binding to its promoter, 
through recruitment by MIZ1 and that MYCC expression switches p53 function from 
a G1 arrest to apoptosis, by increasing the transcription of proapoptotic genes 
PUMA and BAX instead of CDKN1A (Seoane et al., 2002; Sheen and Dickson, 
2002). Additionally MYCN suppresses p21 through direct up-regulation of the 
oncoprotein SKP2. SKP2 is a component of the ubiquitin ligase complex, which 
targets p21 for degradation (Wang et al., 2005). Reduction of SKP2 after MYCN 
knockdown decrease SCFSCP2 mediated degradation of p21, which allows p21 to 
accumulate and induce G1 arrest in p53 wild type cells (Bell et al., 2007; Bell et al., 
2006; Westermann et al., 2007). 
Thus, MYCN plays a dual role in p53 pathway. It impairs the G1 arrest through 
suppression of p21 and sensitizes cells to apoptosis though activation of p53 
transcription. Summary of how MYCN influences p53 signaling and G1/S transition 
is shown in figure 3. 
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Figure 3. G1 checkpoint. Diagram shows the relationship between MYCN, p53 pathway and 
E2F1/Rb.  
 
1.8. Treatment of neuroblastoma  
The therapeutic approaches for neuroblastomas range from observation only to 
aggressive multimodal therapy and are based on the event free and overall survival 
of patients enrolled in clinical trials. Patients with low- or intermediate-risk 
neuroblastoma have event-free survival outcomes graters than 90% (Hero et al., 
2008; Park et al., 2013; Strother et al., 2012). In patients younger than 6 months of 
age with small, localized lesions, observation alone can be a safe treatment option 
(Nuchtern et al., 2012). For patients from low-risk group surgery alone is curative in 
nearly all cases (De Bernardi et al., 2008). Several recent studies demonstrated 
excellent survival rates for children from the intermediate-risk group with reduced 
treatment (Baker et al., 2010; De Bernardi et al., 2009; Kohler et al., 2013; Rubie et 
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al., 2011). Therefore, for the intermediate-risk group the current tendency is to 
reduce the treatment duration, dose of chemotherapeutic agents and radiation 
therapy. 
Patients with MYCN-amplification and/or those, which are older than 18 months of 
age with metastatic disease, are assumed as high-risk. Modern treatment 
strategies for these patients include five to six cycles of induction chemotherapy 
and surgery followed by consolidation therapy with high-dose therapy combined 
with autologous hematopoietic stem cell rescue and irradiation (Pinto et al., 2015). 
However, half of the patients who got clinical remission after induction and 
consolidation therapy will relapse, suggesting the persistence of therapy-resistant 
minimal residual disease (Pinto et al., 2015). The post-consolidation treatment with 
immunotherapy and cytokines plus isotretinoin is now a part of the standard-of-care 
treatment, Figure 4, reviewed in (Pinto et al., 2015). 
 
Figure 4: Current standard treatment strategy for high-risk neuroblastoma. Adapted from 
(Pinto et al., 2015). Therapy includes three treatment blocks: induction (chemotherapy and primary 
tumor resection); consolidation (high dose chemotherapy with autologous stem-cell rescue and 
external-beam radiotherapy (XRT)); post-consolidation (anti-ganglioside 2 immunotherapy with 
cytokines and cis-retinoic acid). Ch – chimeric, CHO – Chinese hamster ovary, GM-CSF – 
granulocyte macrophage colony-stimulating factor, IL-2 – interleukin-2, IV-intravenous, mAb 
monoclonal antibody.  
In general, treatment of patients with residual disease remains to date a big 
challenge. Therefore, the advances in targeted therapies and the understanding of 
the genetics and biology of tumors at the time of original diagnosis are required to 
design a better first-line therapies that will help to reduce relapses.  
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1.9. Topoisomerase-II inhibitors  
Topoisomerase II (Top2) is a very important anticancer drug target. 
Chemotherapeutics, such as doxorubicin etoposide are widely used to treat a broad 
variety of malignancies (Baldwin and Osheroff, 2005; Lieu et al., 2009; Nitiss et al., 
2012; Walker and Nitiss, 2002). Top2 is an enzyme, which simultaneously cleaves 
both DNA strands in order to manage DNA tangles and supercoils (Schoeffler and 
Berger, 2008; Wang, 1998). Most drugs targeting Top2 generate double strand 
breaks (DSBs) as a direct consequence of the catalytic activity of the enzyme 
(Robinson and Osheroff, 1990). Top2 cleaves DNA by forming the covalent 
complexes between the enzyme and DNA, and drugs that disrupt the catalytic cycle 
can trap the enzyme and generate DNA damage (Walker and Nitiss, 2002). Agents 
that inhibit topoisomerase are named topoisomerase poisons to underline the 
importance of cellular damage induced by these drugs. Top2 poisons not only 
generate DNA damage but also inhibit Top2 catalytic activity (Nitiss et al., 1992; 
Nitiss et al., 1993). It has been shown that mammalian cell lines resistant to drugs 
frequently have reduced Top2 activity (Nitiss and Beck, 1996). Furthermore, it was 
found that the G2/M cell cycle checkpoint, that delays progression through mitosis, 
is more activated when Top2 activity is limited (Downes et al., 1994).  
It is well known that drugs targeting Top1 kill cells predominantly in S phase, as 
inhibiting of Top1 generates DSBs only in S phase by collision of replication forks 
with trapped Top1 covalent complexes (Holm et al., 1989; Zhang et al., 2006). 
Therefore, the marker for DSBs, yH2AX phosphorylation does not occur in cells 
treated with drugs targeting Top1 (Huang et al., 2003). In contrast, the killing by 
Top2 targeting agents occurs in all cell cycle phases and yH2AXA phosphorylation 
is detected also in non-replicating cells (Huang et al., 2003). However, replication 
plays a great role in cell death by Top2-targeting agents. Several studies suggested 
that inhibiting replication reduced cell killing by Top2-targeting agents, and that 
progression through S phase enhanced cell death by Top2-targeting agents (Holm 
et al., 1989; Markovits et al., 1987). Currently two related mechanisms explaining 
the generation of DNA damage during S phase by Top2 poisons are described. 
First, collisions of a replication fork lead to disruption of a Top2 covalent complex 
and the generation of DSBs (Howard et al., 1994). A second mechanism suggests 
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that Top2 complexes block the progression of replication forks, and that the 
collapse of a blocked fork generates DSBs (Michel et al., 2004).  
 
1.10. Recognition and repair of double strand breaks 
Cells defend themselves against cytotoxic DNA damage by activating the DNA 
damage repair signaling network that is mostly regulated by sensor kinases:  ataxia 
telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR). ATR is activated 
by single stranded DNA (ssDNA) coated with replication protein A. Whereas ATM is 
activated by DSBs induced, for example, by Top2 inhibitors or ionizing irradiation. 
ATM activates a vast number of responses, such as DNA damage repair, cell cycle 
arrest, gene expression control, chromatin organization, stress control, cell death 
programs (Paz et al., 2011). ATM phosphorylates the histone 2A (H2A) variant 
H2AX (known as yH2AX), which forms foci at the sites of double strand breaks 
(Stiff et al., 2004). yH2AX acts as a docking station for other DNA damage signaling 
proteins such as p53 binding protein 1 (53BP1) and BRCA1 which rapidly 
accumulate at DNA break sites (Panier and Boulton, 2014).  
The two most important mechanisms for repairing DSBs are homologous 
recombination (HR) and non-homologous end-joining (NHEJ) which complement 
each other (Davis et al., 2014; Goodarzi and Jeggo, 2013; Rothkamm et al., 2015). 
ATM promotes the repair of DNA DSBs by homologous recombination (HR) 
through recruitment of BRCA1 to DSBs, or it can antagonize BRCA1 and promote 
non-homologous end-joining (NHEJ) by recruiting p53 binding protein 1 (53BP1) 
(Kastan and Bartek, 2004). BRCA1 and 53BP1 serve as scaffolds that recruit DSB-
effector proteins required for initiation of HR and NHEJ respectively (Escribano-
Diaz et al., 2013; Feng et al., 2013).  
The pathways of DSB repair are based on whether sequence homology is used to 
join the DSB ends (Aparicio et al., 2014). Homologous recombination (HR) requires 
homologous sequences to align DSB ends prior to ligation (Jasin and Rothstein, 
2013). The HR is a highly complex process that involves multiple proteins and 
occurs during the S and G2 phases of the cell cycle when sister chromatids are 
available as repair templates (Heyer et al., 2010; Shrivastav et al., 2008). Briefly, 
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HR involves 5’ to 3’-end-resection, the loading of replication protein A (RPA) on 
single-stranded DNA, the replacement of RPA by RAD51 and invasion of the 
undamaged strand leading to D-loop and heteroduplex formation (Jeggo and 
Lobrich, 2015). Repair synthesis and branch migration can then occur before the 
resolution of Holiday junction intermediates (Jeggo and Lobrich, 2015; Sarbajna 
and West, 2014). Generally, a big number of helper mediator proteins are involved 
in HR.   
Non-homologous end-joining (NHEJ) does not require sequence homology, is 
active throughout the cell cycle and represents the major pathway for repairing 
DSBs (Lieber, 2010). NHEJ is initiated by the binding of Ku70/80 heterodimer to 
blunt or near blunt DNA ends. This leads to recruitment and activation of the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), an ATM-related kinase 
(Dynan and Yoo, 1998). The DNA-PKcs triggers the signaling cascade that 
activates and maintains the downstream repair process. NHEJ involves minimal 
DNA processing and is facilitated by scaffold proteins XRCC4 and XLF that bind to 
DNA Ligase 4, an enzyme responsible for ligating the breaks (Ma et al., 2002; 
Mohapatra et al., 2013). NHEJ is usually described as an error-prone method, 
because NHEJ does not restore sequence information lost in both DNA strands. 
Nevertheless, introduced DNA errors can be corrected post-rejoining by base 
excision or mismatch repair (Jeggo and Lobrich, 2015; Symington, 2014; Zelensky 
et al., 2014).  
NHEJ is quicker that HR and can restore the majority of DSB (Iliakis, 2009). The 
available evidences suggest that in the G2 cell cycle phase, where HR can 
function, NHEJ anyway acts as the pathway of first choice anyway, consistent with 
the fact that KU rapidly binds to the DSBs and resection, the initiating step for HR, 
happens only if NHEJ was not activated (Jeggo and Lobrich, 2015; Shibata et al., 
2011).  
 
1.11. FUCCI method for analysis of cell cycle progression in single cells 
Traditionally the cell cycle transition was difficult to observe in live samples. While 
the transition from M to G1 (cell division) can be determined by morphological 
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changes, the transition from G1 to G2 is very difficult to observe using live cell 
imaging (Sakaue-Sawano et al., 2008). Traditionally, G1/S has mostly been 
observed either after staining with nucleotide analogs (BrdU or EdU), which 
requires sample fixation, or by synchronization of the cell cycle by pharmacological 
reagents (Sakaue-Sawano et al., 2008). 
In 2008, a novel methodology named FUCCI (Fluorescent Ubiquitination-based Cell 
Cycle Indicator), which allows analysis of cell cycle phases in living cells, was 
introduced (Sakaue-Sawano et al., 2008). The FUCCI system bases on two 
components of the DNA replication control system of high eukaryotes, the licensing 
factor Cdt1 and its inhibitor Geminin (Zielke and Edgar, 2015). In higher 
eukaryotes, proteolysis and Geminin mediated inhibition of the licensing factor Cdt1 
are essential for preventing re-replication (Sakaue-Sawano et al., 2008). Due to the 
cell cycle-dependent proteolysis Cdt1 and Geminin proteins oscillate in an inverse 
pattern(Arias and Walter, 2007). Cdt1 peaks in G1 phase just before the onset of 
DNA replication, and declines rapidly after the initiation of S phase. On the other 
hand, Geminin levels are high during S and G2 phase, but low during late mitosis 
and G1 phase (Li et al., 2003; Nishitani et al., 2004). The expression of Cdt1 and 
Geminin is regulated by the sequential regulation of the F3 ubiquitin ligases 
APCCdh1 and SCFSkp2, Figure 4A (Nishitani et al., 2000). The APCCdh1 ubiquitin 
ligase is active in the late M and G1 phases and targets Geminin for degradation, 
while the SCFSkp2 ubiquitin ligase is active only during S and G2 phases and target 
Cdt1 for degradation (Nishitani et al., 2004). Interestingly, the SCFSkp2 complex is a 
direct substrate of the APCCdh1complex but also functions as a feedback inhibitor of 
APCCdh1(Bashir et al., 2004; Wei et al., 2004). 
 
Figure 5. The FUCCI concept. A Cell cycle regulation by SCFSkp2  APCCdh1 maintains bistability between 
G1 and S/G2/M phases. Modified from (Sakaue-Sawano et al., 2008) B Right: cells transfected with mCherry-
Cdt11-120 marked by red fluorescence in G1 and very early S. Left: Cells transfected with mEGFP-
hGeminin11-120 marked by green fluorescence in S/G2/M phases. 
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The FUCCI system relies on fluorescent proteins fused to degrons derived from 
Cdt1 and Geminin (Zielke and Edgar, 2015). These fluorescent FUCCI probes are 
degraded by APCCdh1 and SCFSkp2 during different phases of the cell cycle, and 
thereby allow the visualization of living cells in either G1 or S/G2/M , Figure 4B. 
Although the original FUCCI system is based on dual probes, it is possible to 
determine the cell cycle stage with a single FUCCI probe.  
Sakaue-Sawano and coworkers first fused the complete human Cdt1 protein to a 
monomeric version of Kusabira Orange (mKO2), but the ectopic expression of this 
construct interfered with cell cycle progression (Sakaue-Sawano et al., 2008). 
Therefore the authors generated different deletion constructs and found that an N-
terminal fragment of hCdt1 (hCdt130-120) is sufficient for degradation during S and 
G2 phases. This fragment does not have the Geminin-binding region, but obtains 
the CY motif (amino acids 68-70), which is critical for mediated proteosomal 
degradation (Nishitani et al., 2006). Interestingly, the original G1 sensor is only 
functional when conjugated with mKO2 or mCherry, while the fusions with the 
AzamiGreen, EGFP or RFP1 were constantly expressed during the whole cell cycle 
(Sakaue-Sawano et al., 2011; Sakaue-Sawano et al., 2008). For the G2 sensor, 
Sakaue-Sawano and coworkers also generated a fusion protein consisting of 
mKO2 and the N-terminal region of hGeminin (hGem1-110) that allows robust 
detection of S/G2/M phase. In contrast to hCdt130-120, hGem1-110 shows normal cell 
cycle oscillations in combinations with various fluorescent proteins such as mAG, 
mCyan, EGFP, Venus, or mCherry (Sakaue-Sawano et al., 2013; Sakaue-Sawano 
et al., 2011).  
To date, a broad range of FUCCI-expressing cell lines and several model systems, 
including flies, fish, mice and plants are available for a wide range of researches for 
studies of diverse biological processes. Although only a short time has passed 
since introduction of the FUCCI method, the fundamental insights into how cells 
establish quiescence and how G1 phase length impacts the balance between 
pluripotency and stem cell differentiation are already provided (Zielke and Edgar, 
2015). 
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1.12. Aims of the study 
MYCN mediates cells sensitive phenotype that results in the fast initial response to 
the induction therapy observed in MYCN-amplified neuroblastoma patients and cell 
lines. However, MYCN tumors frequently relapse, suggesting that some MYCN-
amplified cells find the way to escape cell death and are capable to quickly regrow 
from and metastasis. 
This study is aiming to understanding of the mechanisms by which a small fraction 
of cells (‘resisters’) survive cytotoxic therapy, repair drug-induced DNA damage, 
and, resume clonal proliferation thereafter. The project addresses the following 
questions: 
1. Which properties help cancer cells to survive therapy?  
For this the molecular and phenotypic responses of MYCN tunable neuroblastoma 
cells to the chemotherapy are analyzed on the population and on the single cell 
level. The influence of cell cycle arrest, DNA damage checkpoint deregulation and 
DNA damage repair is investigated. 
2. Can resister cells be sensitized to chemotherapy and prevented from 
resuming proliferation after treatment? 
With the obtained knowledge about molecular mechanisms involved in 
chemotherapy resistance novel combinations of chemotherapy and molecularly 
targeted drugs will be designed to improve the effect of first-line therapy. 
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2. Materials and Methods 
2.1. Materials 
Research equipment 
Bioanalyzer        Agilent 
Cell culture hood HERA      Heraeus 
Centrifuges Eppendorf, 
Beckman Coulter 
Qbit        Qubit 
Light Cycler 480      Roche 
Microscope Nikon Ti-E     Nikon 
Microscope Olympus, CKX41    Olympus 
Miltenyi MACSQuant Analyser    Miltenyi 
SDS-gel-electrophoresis chamber   BioRAD 
Steri-cult CO2 incubator     Thermo Scientific 
Transfer chamber                 BioRAD 
Tecan Infinite M 200     Tecan  
NanoDrop ND-1000 spectrophotometer   NanoDrop 
Vortex Genie       NeoLab 
Thermo water bads      GFL, Hans Byaer, Julabo 
 
Molecular biology reagents  
4x Laemmli Sample Buffer    BioRad 
ABSOLUTE qPCR ROX mix    Thermo Scientific 
Agencourt AMPure XP beads    Beckton Dickinson 
Bovine serum albumin (BSA)    Roche Diagnistics  
Cell Titer Blue      Promega 
ERCC Spike-in control     Life Technologies 
QBit RNA assay       Life TechnologiesMethylene  
Methylene Blue      Merck 
PBS        Santa Cruz 
Ponseau S       Sigma 
Prolong       Life Technologis 
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Running buffer       Bio-Rad 
Spike-In       Life technologies 
TBS        Santa Cruz 
Transfer Buffer       Bio-Rad 
 
Kits for molecular biology 
BCA Protein Assay Reagent     Pierce 
Click-iT EdU Flow Cytometry Assay Kit   Life Technologies 
iDeal ChIP-Seq Kit      Diagenode 
Effectene Transfection Ragent    Qiagen 
NEBNext ChIP-Seq library Prep Master Mix set Kit New England Bioscience 
ScriptSeq Complete Gold Kit (Human/Mouse/Rat) Epicenter 
Senescence β-Galactosidase Stainig Kit  Cell Signalling 
First Strand cDNA Synthesis Kit    Thermo Scientific 
RiboGold Kit       Epicenter 
RNeasy mini Kit       Qiagen 
 
 
Chemicals and Reagents 
4IPBA        Sigma  
4,6-diamidino-2-phenylindol (DAPI)   Sigma 
DMSO        AppliChem  
EDTA        Sigma  
Ethanol        Sigma 
Formaldehyde 37%      Sigma 
Formaldehyde 4%      BioLegend 
FxCycle Violet Stain     Life Technologies 
Glycine       AppliChem, Darmstadt 
Goat Serum        Sigma 
Hydrogen peroxide       Sigma  
Isopropanol        Greiner Bio One  
luminol        Sigma  
Methanol        Greiner Bio One 
Nuclease-free water     Ambion 
Triton X-100        Sigma  
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Materials 
Menzel-Gläser Polysine Slides    Thermo Scientific 
PVDF Membrane, 0.45mm     Schleicher and Schüll 
Whattman 3MM Paper     Whatman, Dassel 
 
Table 4 Antibodies for Western Blot 
Specificity Host Supplier/Catalog number 
MYCN Mouse  Santa Cruz sc-53993 
P53 Mouse  Santa Cruz sc-126 
P21 Mouse  Cell Signaling 
MDM2 Mouse  BD Biosciences 556353 
BAX Rabbit Cell Signaling 2772S 
Actinβ Mouse  Sigma-Aldrich A-5441 
Anti Mouse-HPR Goat polyclonal Santa Cruz sc-2031 
Anti Rabbit-HPR Goat polyclonal Santa Cruz sc-2030 
Molecular weight marker for immunoblotting 
BenchMark, pre-stained protein Ladder 10748-010 Invitrogen 
 
Table 5 Antibodies and Isotypes for FACS 
Specificity Host Supplier/Catalog number 
P-p53 (S15) Alexa (R) 488 Conjugate  Mouse Cell Signaling 9235S 
p21 Waf1/Cip1 Alexa (R) 488 Conjugate  Rabbit Cell Signaling 5487S 
p-Rb (S807/811) XP(R) PE Conjugate Rabbit Cell Signaling 11917S 
pATM (Ser1981) PE Conjugate Mouse BioLegend 651203 
Skp2 Rabbit Cell Signaling 2652S 
mAb IgG1 Isotype Control Alexa (R) 488 Conjugate Mouse Cell Signaling 4878S 
mAb IgG  XP(R) Isotype Control Alexa (R) 488 
Conjugate 
Rabbit Cell Signaling 2975S 
mAB IgG1, k Isotype Control PE Mouse BioLegend 400112 
mAb IgG  XP(R) Isotype Control PE Conjugate Rabbit Cell Signaling 5742S 
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Anti-rabbit IgG (H+L), F(ab)2 Fragment Alexa (R) 
488 Conjugate 
Rabbit Cell Signaling 4412S 
 
Table 6 Antibodies for Immunofluorescence 
Specificity Host Supplier/Catalog number 
Ki67 Mouse Cell Signaling 9449S 
yH2AX Rabbit Cell Signaling 9718S 
53BP1 Rabbit Santa Cruz sc-22760 
Anti-Rabbit Alexa Fluor® 405 IgG (H+L) Goat Life Technologies A31556 
Anti-Rb IgG (H+L) Cy5.5 Conjugated Goat Life Technologies L42018 
Anti-Rabbit Alexa Fluor® 488 IgG (H+L) Goat Life Technologies A11034 
 
Table 7 Antibodies for Chip-Seq 
Specificity Host Supplier/Catalog number 
H3K9me3 Rabbit Abcam 8898 
H3K4me3 Rabbit Abcam 8580 
H3K27me3 Mouse Abcam 6002 
 
Table 8 Taqman® Real-Time PCR Assays 
Gene Assay ID 
MYCN  Hs00232074_m1 
 C-MYC Hs00153408_m1 
TP53 Hs01034249_m1 
CDKN1A Hs00355782_m1 
BAX Hs00180269_m1 
BBC3 Hs00248075_m1 
E2F1 Hs00153451_m1 
SKP2 Hs01051864_m1 
CCNA2 Hs00996788_m1 
CCNE1 Hs01026536_m1 
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CCND1 Hs00765553_m1 
GAPDH Hs02758991_m1 
UBC Hs00824723_m1 
HMBS Hs00609296_m1 
SDHA Hs00188166_m1 
All TaqMan assays were obtained from ThermoFisher Scientific 
 
Drugs 
Doxorubicin        Tocris 
Neocarciostatin       Sigma 
RO-3306 (CDK1 inhibitor)      Calbiohem 
LEE011 (CDK4 inhibitor)      Selleckchem 
KU-60019 (ATM inhibitor)      Tocris 
AZD7762 (Chk1&Chk2 inhibitor)     APExBio 
LY2603618 (Chk1 inhibitor)     APExBio 
VE-821 (ATR inhibitor)      Calbiochem 
 
Antibiotics for cell culture 
Blasticidin        Sigma 
Penicillin/Streptomycin      PanReac AppliChem 
G418                 Sigma 
Hygromycin B       Sigma 
Puromycin        BD Clontech 
Zeocin        Invitrogen 
Doxycycline        BD Clontech   
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Media and supplement for cell culture 
RPMI 1640 (1mM L-Glutamine, 25mM Hepes) Gibco, Life 
Technolofies 
RPMI 1640 (with L-Glutamine, without Phenol Red) PAA, The Cell Culture 
Company 
Fetal Bovine Serum (FCS) Gibco, Life 
Technolofies 
 
Plasmids 
The pMOWS_puroR_mCherry_hCdt1 and pMOWS_puroR_mEGFP_hGem 
constructs were kindly provided by Prof. Ursula Klingmüller. The first construct 
possesses a part of hCdt1 (1-300) and the second a part of hGeminin (1-60). These 
parts are degraded in a cell cycle dependent manner. Both plasmids have 
puromycin resistance. 
The pRRL-mCherry-53BP1 construct was kindly provided by Prof. Alexander 
Loewer. This is a lentiviral vector expressing a fragment of human 53BP1 (1228-
1922) fused to mCherry under the Ubiquitin C promoter. 
 
Table 9 Tissue culture cell lines used in the study 
Cell Line Description Reference Selective 
antibiotics 
SH-EP MYCN – non-amplified 
neuroblastoma cell line 
(Ross et al., 
1983) 
 
TET21N 
Derived from SH-EP, transgenic 
inducible MYCN, non amplified 
neuroblastoma cell line 
(Lutz et al., 
1996) 
90 µg/ml Hygromycin  
200 µg/ml G418  
IMR5/75_shRNA 
MYCN 
MYCN - amplified neuroblastoma 
cell line, expresses MYCN shRNA 
under control of tetracycline 
repressor 
(Muth et al., 
2010) 
5 µg/ml Blasticidin, 
45 µg/ml Zeocin 
IMR32 _shRNA 
MYCN 
MYCN - amplified neuroblastoma 
cell line, expresses MYCN shRNA 
under control of tetracycline 
repressor 
 
5 µg/ml Blasticidin 
180 µg/ml Zeocin 
SH-SY5Y_MYCN 
Derived from MYCN non amplified 
neuroblastoma cell line SH-SY5Y, 
transgenic inducible MYCN 
 
7.5 µg/ml Blasticidin, 
1 mg/ml G418 
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TET21N_hCdt1 
Derived from SH-EP, transgenic 
inducible MYCN, with recombinant 
hCdt1 (30-120) 
Generated in 
the present 
study 
90 µg/ml Hygromycin  
200 µg/ml G418 
7.5 µg/ml Puromycin 
TET21N_Geminin 
Derived from SH-EP, transgenic 
inducible MYCN, with recombinant 
hGeminin (1-60) 
Generated in 
the present 
study 
90 µg/ml Hygromycin  
200 µg/ml G418 
7.5 µg/ml Puromycin  
IMR5/75_hCdt1 
MYCN - amplified neuroblastoma 
cell line, expresses MYCN shRNA 
under control of tetracycline 
repressor, has recombinant hCdt1 
Generated in 
the present 
study 
5 µg/ml Blasticidin 
45 µg/ml Zeocin 
2 µg/ml Puromycin 
TET21N_hGeminin 
Derived from SH-EP, transgenic 
inducible MYCN, with recombinant 
hGeminin (1-60) and h53BP1 
Generated in 
the present 
study 
90 µg/ml Hygromycin  
200 µg/ml G418 
7.5 µg/ml Puromycin 
2 µg/ml Blasticidin 
 
Software 
Adobe Photoshop CS5 12.0.4  
Systems Inc. 
Inkscape 
FIJI 
FlowJo 7.6.5 
Prism 6 
 
2.2. Methods 
2.2.1. Cell culture methods 
2.2.1.1 Culturing and cryoconservation of human neuroblastoma cells 
All cells were cultivated in RPMI1640 supplemented with 100 U/ml Penicillin/ 
Streptomycin, and 10% FCS at 37°C, in 5% CO2 atmosphere in a humidified cell 
culture incubator. The cell culture medium was substituted every 3-4 days, and 
cells were split at ration 1:5 when they reached subconfluent density.  Adherent 
cells were removed from the substratum by versenization. Visual observation of cell 
morphology was conducted under the Zeiss Axiovert microscope, equipped with 
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phase-contrast and bright-field optics. The conservation cells were harvested and 
resuspended in 4 ml of an ice-cold cryoconservation medium (RPMI with 40% FCS, 
10% DMSO). The cellular suspension was dispensed into cryocontainers and 
incubated at least 24h at -80C prior to deposition into a liquid nitrogen tank for long 
time storage. For recultivation, frozen cells were quickly thawed and the 
cryoconservation medium was substituted with a warm fresh growth medium. 
2.2.1.2 Transfection of plasmids and selection of transfected cells 
In the present study all transfections were carried out using the Effectene 
Transfection Reagents. This reagent is a non-liposomal lipid formulation allowing 
high transfection efficiency with minimal cytotoxicity. Plasmids were transfected into 
cells, which were seeded 18-24h before transfection. Transfection was performed 
according to manufactural instructions using 1 µg DNA. The transfection medium 
was replaced by the fresh complete medium 24h post transfection. Selection of 
stably transfected cells was initiated 24h post transfection by addition of appropriate 
antibiotics into the growth medium.  After selection, transfected cells were sorted 
into single cells using fluorescence activated cell sorting to generate clonal 
populations. Individual clones were expanded and analyzed using FACS analysis 
or time-lapse microscopy. 
2.2.1.3. Drug treatment 
Doxorubicin (DOX) was used at the concentration of 0.1µg/ml for SHEP, TET21N 
and SH-SY5Y or at the concentration of 0.05µg/ml for IMR5/75 and IMR32 cells. 
For the monitoring of the cells after treatment at the indicated time durations the 
medium with DOX was washed out and replaced with a normal growth medium. 
The CDK1 inhibitor (RO-3306), CDK4 inhibitor (LEE011), ATM inhibitor (KU-
60019), ATR inhibitor (VE-821), Chk1&Chk2 inhibitor (AZD7762) and Chk1 inhibitor 
(LY2603618) were used with the concentrations 7.5 µM, 4 µm, 10 µM, 5 µM,       
300 nM and 3 µM respectively.  
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2.2.1.4. Colony formation assays 
Cells were harvested and 1x104 to 6x104 cells were re-plated into 6 well plates with 
fresh medium. 14 days after re-seeding cells were fixed with 4% PFA, stained with 
methylene blue and imaged. The number of colonies was counted using FIJI’s 
particle analyzer.  
2.2.1.5 Senescence assay 
Cells were fixed with a 1% paraformaldehyde fixative solution, washed twice in 
1xPBS and stained with a β-Galactosidase staining kit (Cell Signaling) according 
the manufacturer’s instructions. Brightfield and DAPI images were captured with a 
color Dr. Gregor Mönke. A color threshold was applied on an ellipsoid stripe 
surrounding a cell’s nucleus. The mean measured intensity of the chosen green 
color component (30˚ - 120˚ in HSB space) was recorded for every imaged cell.  
2.2.1.6 Calculation of growth curves after drug treatment 
At the appropriate time points cells were dethatched with versene. 1mL of cell-
versene suspension was collected and 100 µL were counted with the MACSQuant 
Analyser (Milteny) using propidium iodide staining to exclude dead cells. 
 
2.2.2. FACS analysis 
2.2.2.1 Cell cycle and Sub G1 analysis  
Adherent and non-adherent cells were harvested and centrifuged for 5 min at 800g. 
The pellets were fixed with ice-cold 70% ethanol and incubated at -20°C overnight. 
Cells were washed in PBS, stained for 30min with DAPI or with VioBlue (Life 
Technologies) and analyzed with the Miltenyi MACSQuant Analyzer. Data were 
analyzed using FlowJo software, and the Dean-Jett-Fox algorithm for cell cycle 
analysis. Cells with a DNA-content below that of the G1-fraction were considered 
dead.   
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2.2.2.2 Antibody staining  
106 cells were pre-fixed with 4% paraformaldehyde (PFA) for 15 minutes at room 
temperature (RT), then re-suspended in ice-cold methanol and incubated overnight 
at -20°C. Cells were then washed in PBS, incubated for 30min in washing buffer 
(1%BSA, 0,1% TritonX in PBS) and stained with fluorescein-conjugated primary 
antibodies for 1 h at RT (Table.2). After washing the cells were stained with Violet-
Blue dye for cell cycle analysis.  
2.2.2.3 EdU incorporation  
Cells were incubated with 10 µM EdU for 1h prior to collection. 106 cells were fixed, 
permeabilized and stained with the Click-iT Plus EdU Flow cytometry Assays Kit. 
2.2.2.4 FACS-Single cell sorting (Cell cycle outgrowth) 
TET21N_hCdt1 cells were harvested and resuspended in ice-cold medium. Cell 
sorts were performed using FACSariaII (BD). For each conditions ~600 or more 
single cells were sorted into 96-well plates according to their cell cycle status. 3 
weeks after re-seeding, cells were stained with Cell Titer Blue assay, imaged and 
the number of colonized wells counted. Three biological replicates were performed. 
 
2.2.3. Live-cell microscopy 
Cells were grown on 8-well Ibidi µ-slides or Lab-Tek chamber slides in phenolred-
free RPMI 1640 medium and imaged every 10-20 min for up to 2 weeks under 
controlled growth conditions at 37°C, 5% CO2 and 80% humidity (Pecon incubator). 
The growth media was changed every 2-3 days. Images were acquired with an 
inverted widefield microscope (Nikon Ti-E) using an EMCCD camera (Andor iXON3 
885) and a 20x lens (CFI Plan Apochromat DM 20x, NA 0.75). Phase contrast 
images were acquired in addition to fluorescence using a light engine lamp 
(Lumencor) and filters DAPI, GFP (Semrock) and RFP (AHF).  
Cells were tracked in FIJI (version 1.48d) (Livak and Schmittgen, 2001) using the 
plugin MTrackJ (Meijering et al., 2012) for manual tracking. Automatic nuclei 
segmentation and tracking were done by Dr. Gregor Mönke using ImageJ-based 
custom written software.  
Materials and Methods 
32 
2.2.4. Real-time quantitative PCR 
Total RNA was isolated with the RNeasy Mini Kit (Qiagen), following manufacturer’s 
instructions. Nucleic acids were quantified in solution using NanoDrop ND-1000 
spectrophotometer by measuring absorbance at 260 nm.  
RNA for the gene expression measurement was reverse transcribed using the 
RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo scientific) according to 
manufacture instructions. Samples to be used in real-time quantitative PCR were 
diluted with nuclease-free water to the final concentration of 2 ng/µL (equivalent of 
total RNA) and stored at -20°C until use. 
DNA was quantified in 384-well format using the LightCycler 480 Real-Time PCR 
System, Table5. For the quantitative gene expression studies, cDNA in the amount 
of 10 ng of equivalent of total RNA was used per well. 5 µL of cDNA (2 ng/µL) was 
mixed with 6 µL of enzymatic master mix, yielding 11 µL total sample volume. The 
mRNA level of each target gene was normalized to the relative average amount of 
the internal reference genes GAPDH, UBC, SDHA or HMBS. The internal reference 
genes and the target genes were analyzed in parallel for each sample. The relative 
gene expression was calculated using the comparative cycle crossing point (∆∆Cp) 
method (Livak and Schmittgen, 2001). 
 
2.2.5. RNA-sequencing  
RNA was extracted from 1x106 cells using the RNeasy mini kit (Qiagen) with a 
separate step for DNAse I digestion (Fermentas). RNA amount was determined 
using a Qbit (Life Technologies) and quality assessed using a Bioanalyser Total 
RNA kit, or a small RNA Kit (Agilent). In order to maintain a record of the cell 
number throughout library preparation, the same amount of ERCC Spike-in control 
mix-1 (Life technologies) was added to each sample prior to processing (1 µl of a 
1:10 dilution of mix-1). RNA from each sample was processed using the RiboGold 
kit (Epicentre) to remove rRNA. The concentration of the resulting RNA was 
measured using the Qbin RNA assay. The remaining rRNA-depleted was then used 
to prepare libraries for sequencing using ScriptSeq Complete Gold Kit low input  
(Epicenter). The Agencourt AMPure XP beads (BeckmanCoulter) were used to 
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purify the cDNA.  Barcodes for individual samples were added in order to multiplex 
6 samples in each sequencing lane. 14 cycles of enrichment PCR were performed 
prior to size selection with Agencourt Ampure beads (Beckton Dickinson) to select 
cDNA with a narrow size distribution around 270 base pairs in length. The qualities 
of libraries were assessed using a DNA1000 chip on a Bioanalyser (Agilent) to 
ensure the correct size of libraries and the concentration was measured using the 
Qbit DNA assay. Sequencing was performed on an Illumina platform with HiSeq 
2000 Pair-end 100bp sequence type. Bioinformatic analysis of RNA-Seq data was 
performed by Dr. Chunxuan Shao. 
 
2.2.6. Chromatin Immunoprecipitation and Sequencing (ChIP-Seq) 
Chromatin Immunoprecipitation ChIP experiments with TET21N cells were carried 
out using iDeal ChIP-seq Kit from Diagenode according to the manufacturer’s 
instructions. For fixation 106 TET21N cells were incubated for 10min at room 
temperature with 1% formaldehyde. Cross-linking was terminated by addition of 
glycine to a final concentration of 125 mM. Subsequently cells were incubated for 
20min at 4°C with a lysis buffer, nuclei were collected by centrifugation for 15min at 
20.000xG and 4°C and resuspended in a sonication buffer. The chromatin was 
fragmented by sonication (Covaris) to an average size of 150bp. 1% of material 
was saved as “Input”. Antibodies, Table4,  were added to the sheared chromatin 
and DiaMag Protein A beads and incubated on a rotating wheel over night at 4°C. 
Rabbit and mouse normal IgG were used as negative controls. The beads were 
washed four times with washing buffers. Immune complexes were disrupted by 
eluting 30min at room temperature with the elution buffer. Eluates were reverse 
cross-linked by heating at 65°C for 4h and DNA was purified with magnetic beads. 
Two biological replicates for histone modifications were sequenced using Illumina 
HiSeq 2000 (50bp single-end) sequencing technology. 12 indexes were used per 
sequencing lane.  
Library preparation for Illumina 10ng of chromatin-immunoprecipitated DNA was 
end repaired and dA tailed. Subsequently, the adaptor was ligated to the dA-Tailed 
DNA. DNA was cleaned up using AMpure XP beads after each step. Adaptor 
ligated DNA was selected in size with AMpure XP beads using different DNA to 
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beads ratios to an average fragment size of 280bp. As the last step, size-selected 
and adaptor-ligated DNA was enriched by PCR with different index primers and 
cleaned up using AMpure XP beads. Purified library DNA was quantified with Qubit 
2.0 and fragment size was assessed using Bioanalyzer (Agilent high sensitivity 
chip). Bioinformatic analysis of RNA-Seq data was performed by Dr. Chunxuan 
Shao. 
 
2.2.7. Immunofluorescence 
Cells were seeded onto sterilized glass slides (Thermo Scientific) placed in the cell 
culture dishes and cultured as appropriate. Cells were fixed with 4% PFS for 5 min 
at RT, washed 3x with PBS, permeabilized with 0.5% Triton X-100 in PBS for 5min, 
washed again and blocked with Goat Serum diluted 1:10 for 30 min. The glass 
slides were incubated with primary antibodies diluted in a blocking buffer for 1h at 
RT in a dark humid chamber (Table3).  After washing 3x with PBS, glass slips were 
incubated with diluted fluorescence conjugated secondary antibodies for 1h at RT, 
Table 3. After 3x washing with PBS, the nuclei were counterstained with DAPI. 
Images were captured with an EMCCD camera (Andor iXON3 885) using a 60x oil 
lense. 
 
Quantification of proteins via SDS-PAGE and western blotting 
Cells were seeded onto 6-well plates. Directly before protein isolation, ice-cold 
RIPA buffer was supplemented with 1x Halt Protease Inhibitor Cocktail and 5mM 
EDTA. Cells were washed with ice-cold PBS, the plate was placed on ice and cells 
were lysed with 50 µL of complete lysis buffer by scraping with a cell scraper. The 
lysate was transferred to pre-chilled 1.5mL tubes, agitated for 30 min at 4°C and 
centrifuged at 4°C, 10000xG for 20 min. The supernatant was transferred to a new 
1.5mL tube and stored at -80°C. Before use, lysates were boiled for 10 min at 95°C.  
BCA assay Protein samples were diluted 10x with a RIPA buffer and quantified 
with a BCA Protein Assays Reagent according to the manufacturer’s instructions. 
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The protein concentration was calculated from a standard curve prepared using 
serial dilutions of BSA (25-2000 µg/mL). 
SDS-PAGE The lysates were separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE). The 4x Lämmli method of discontinuous 
electrophoresis was applied (Laemmli, 1970). 50 µg of total protein lysate was 
mixed with a Protein Loading Buffer, supplemented with 20% β-mercaptoethanol, 
denatured for 5 min at 95°C and loaded into Any KDTM Criterion TGX Gels 
(BioRad). The gel was run at 120V, after the run, stacking gel was removed and 
separating gel was equilibrated for 15 min in the transfer buffer.  
Western blot and immunodetection of proteins by ECL The proteins were 
transferred to a Polyvinylidene Difluoride (PVDF) membrane. The PVDF membrane 
was activated for 1 min in 100% methanol, followed with equilibration in the transfer 
buffer for 10 min. The transfer was performed in a fully submerged system from 
BioRad Transblot for 1 h and at 100V/400 mA. After transfer, the membrane was 
blocked with 5% BSA in 1x TBS-T buffer for one hour. After blocking, the 
membrane was washed 3x 5min with 1xTBST and incubated overnight with a 
primary antibody at 4°C (Table1). The membrane was washed 3 x 5min with 
1xTBST, incubated for 1 h with the secondary antibody conjugated to horseradish 
peroxidase (Table1) and washed 3x 5 min with 1x TBST. 
Detection was performed using non-commercial ECL solution. 6.6µL of H202 were 
added directly before use to the 20 mL of ECL solution. The blots were incubated 
for 1 min with the ECL solution and luminescence was detected with the CCD 
camera.   
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3. Results 
3.1. MYCN determines growth phenotype  
3.1.1. Model systems to examine MYCN effects on cell cycle 
The effect of MYCN on cell cycle progression and response to chemotherapy was 
studied in two MYCN-regulatable neuroblastoma cell lines: SHEP TET21N (later 
TET21N) and IMR5/7. TET21N is a non-MYCN amplified, p53 wild-type cell line, 
which harbors a tet-off system with transgenic inducible MYCN expression (Lutz et 
al., 1996). In this system MYCN can be switched off by the presence of doxycycline 
in the media, Figure 6A. IMR5/75 are MYCN-amplified cells, containing around 75 
copies of the MYCN oncogene and harboring tet-inducible shRNA against MYCN, 
(Muth et al., 2010). In these cells, by adding doxycycline to the media MYCN 
protein expression can be reduced to approximately 35%, Figure 6B. These two 
cell lines provide two complementary means of controlling the MYCN level, with 
tunable inducible overexpression of integrated MYCN transgene in TET21N cells 
and tunable knockdown in MYCN-amplified IMR5/75 cells. 
Cell cycle analysis of exponentially growing cells revealed that switching MYCN 
expression to high or low levels influences the proportion of cells in different cell 
cycle phases. Thus, under MYCN-high conditions cells have a higher fraction of 
cycling cells (S and G2/M) and a lower fraction of cells in G1 when compared to 
MYCN-low conditions, Figure 6C,D. Live-cell imaging of TET21N cells revealed that 
MYCN accelerates cellular proliferation, Figure 6E. The calculated average 
doubling times were 13.8 hours for MYCN-high cells versus 18.2 hours for MYCN-
low cells.  
The main advantage of using TET21N cells is that they can be used for live-cell 
imaging and analysis on the single cell level. TET21N cells belong to the substrate 
adherent type of neuroblastoma cells and are characterized by a flat oval nucleus 
with abundant cytoplasm. These features allow easy and precise segmentation and 
tracking of cells. In contrast, IMR5/75 cells belong to the neuronal type and are  
characterized by a round nucleus, high nuclear to cytoplasm ratio and a low 
substrate adherence, which makes them extremely difficult to analyze on the single 
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cell level. Therefore, in the present study the TET21N cell line was predominantly 
used to examine the effects of MYCN in the single cells.  
 
Figure 6. MYCN influences cell cycle and cell growth in MYCN-amplified and MYCN- 
overexpressing cell lines A. Western blot analysis of MYCN protein expression in TET21N cells 
measured 48h after incubation in medium with or without of doxycycline. B Cell cycle in TET21N 
cells under MYCN-high and MYCN-low conditions measured by FACS. C Western blot analysis of 
MYCN protein expression in IMR5/75 cells measured 48h after incubation in medium with or without 
of doxycycline. D Cell cycle in IMR5/75 cells under MYCN-high and MYCN-low conditions measured 
by FACS. E MYCN-dependent growth curves in TET21N cells. Cells were imaged for 80h and the 
absolute cell numbers were calculated using FIJI software. 
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3.1.2. MYCN shortens lengths of cell cycle phases 
To better understand the effect of MYCN on cell cycle progression and to monitor 
cell cycle phases in individual living cells the FUCCI system was used. EGFP-
Geminin construct was transfected into TET21N cells. EGFP-Geminin slowly 
accumulates in cells after division, reaches maximum levels as cell enter mitosis, 
and then rapidly degrades during cytokinesis, Figure 7A,C. The mCherry_Cdt1 
construct was transfected into TET21N and into IMR5/75 cells. Cdt1 is highly 
expressed in G1 phase, but after G1/S transition Cdt1 level rapidly drops and in G2 
phase cells remain mostly Cdt1 negative, Figure 7B,C. 
To observe cell cycle progression directly in individual cells, live cell imaging of 
TET21N cells with FUCCI sensors was performed. The dynamics of Cdt1 and 
Geminin expression allow do determine the lengths of cell cycle phases in single 
cells even if cells transfected with only one of the FUCCI sensors, Figure 7C. 
Analysis of single cells with Cdt1 FUCCI marker showed fast G1/S progression of 
MYCN-high cells, with lower Cdt1 accumulation, versus long residence in G0/1 in 
MYCN-low cells with higher Cdt1 accumulation. Geminin FUCCI marker also 
revealed that MYCN-high cells transit from G1 into G2 earlier as compared to 
MYCN-low cells and have lower accumulation of Geminin during G2 phase, Figure 
6D. 
Imaging and analyzing of cells with FUCCI sensors identified that high MYCN levels 
decrease the total length of cell cycle, Figure 7E. This MYCN effect exerted mainly 
in G1, with MYCN-high cells showing faster and more synchronous G1/S 
transitions. However, also the S/G2/M duration was shorter in MYCN-high cells.  
These findings indicate that MYCN accelerates the cell cycle entry by shortening 
the lengths of both cell cycle phases, whereas the G1 phase appears to be more 
affected by MYCN.  
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Figure 7. MYCN shortens G1 cell cycle phase. A FACS analysis of Geminin expression 
throughout the cell cycle in TET21N cell stably transfected with GFP-Geminin construct. B FACS 
analysis of Cdt1 expression throughout the cell cycle in TET21N and IMR5/75 cells stably 
transfected with mCherry-Cdt1 construct.  C Single-cell resolved cell cycle dynamics for TET21N 
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cells with mCherry-Cdt1 (red) and for TET21N cells with GFP-Geminin (green) captured by time-
lapse microscopy. D Quantification of fluorescence intensity of G1 or G2 FUCCI markers in TET21N 
single cells. For mCherry-Cdt1 a rapid reduction in Cdt1 intensity indicates S-phase entry. For GFP-
Geminin cells an increase in Geminin intensity indicates S-phase entry. E Distribution of total cell 
cycle lengths and duration of cell cycle phases of MYCN-low (blue) and MYCN-high (red) 
populations in TET21 cells.  
 
3.2. MYCN sensitizes cells to chemotherapy-induced death and drives cellular 
regrowth after chemotherapy 
3.2.1. TET21N cells have active cell cycle checkpoints after DNA damage 
After showing that MYCN accelerates the cell cycle in untreated cells, it was 
analysed how MYCN affects the cells cycle arrest and checkpoints activation during 
DNA damage.  For this, TET21N cells were treated with the DNA-damage inducing 
chemotherapeutic drug, doxorubicin (DOX), which is commonly used to treat 
neuroblastoma.  
Cell cycle progression of DOX treated cells was analysed by FACS and the 
proportion of proliferating (S phase) cells was visualised by EdU staining. Analysis 
of cell cycle showed that G1/S checkpoint was activated after 9 hours of treatment 
in MYCN-low cells and after 12 hours of treatment in MYCN-high cells. Which was 
indicated by the abolishing of cells in the S phase, Figure 8A. This resulted in an 
extended arrest of MYCN-low and MYCN-high cells in both G1 and G2 cell cycle 
phases.  
To investigate the cell cycle transitions on the single cell level the live-cell imaging 
of TET21N_Cdt1 cells during DOX treatment was performed. Tracking of single 
cells showed that both G1/S and G2/M checkpoints were affected by MYCN, Figure 
8B,C. First, MYCN-high cells were shown to transit from G1 to S and from G2 to M 
approximately 2 to 3 hours longer when compared to MYCN-low cells, which 
suggests the delayed activation of the cell cycle checkpoints in the presence of 
MYCN. Second, MYCN increased the proportion of cells making checkpoint 
transitions after DNA damage. Thus, 78% of G1 MYCN-high and 53% of G1 
MYCN-low cells proceeded into S phase. The G2/M transition was observed in 32% 
and 54% of G2 cells with low and high MYCN respectively, Figure 8C.  
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Taken together, both MYCN-low and MYCN-high cells arrest in G1 and G2 phases 
after DOX treatment. Strikingly, the cell cycle arrest occurs only several hours after 
induction of DNA damage and cells still have time to move from one cell cycle 
phase to the next. MYCN delays the activation of the cell cycle checkpoints and 
increases the proportion of transiting cells.  
 
Figure 8. TET21N cells have active cell cycle checkpoints after DNA damage. A Cell cycle 
progression of cells treated with DOX for 24h at different time points measured by FACS. DNA 
synthesis (S-phase) determined by EdU incorporation versus DNA content. n=3; a representative 
experiment is shown. B Transitions of cells through G1/S, and C through G2/M cell cycle 
checkpoints at the first 20 hours during DOX treatment. TET21N_Cdt1 cells were imaged every 15 
minutes. Cell cycle transitions were determined according to changes in Cdt1 intensity. Cells were 
tracked in FIJI using the plugin MTrackJ for manual tracking.  
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3.2.2. MYCN sensitizes cells to chemotherapy-induced death and rescues 
cells from cell cycle arrest. 
After finding that DNA damage induces cell cycle arrest in both MYCN-low and 
MYCN-high cells it was examined how MYCN influences cellular behaviors after 
treatment. For this, 72h after DOX treatment the drug was washed-out and cells 
were subsequently incubated in drug-free media and analyzed at different time 
points, Figure 9A.  
The analysis of extended live-cell imaging showed that during treatment cells 
underwent cell cycle arrest and the fraction of cells died, as indicated by decrease 
in relative cell numbers, Figure 9B. MYCN-high cells were more sensitive to cell 
death during and after treatment. Interestingly, after prolonged incubation in drug-
free media, MYCN-high cells showed the capacity to regrow, whereas MYCN-low 
cells stayed arrested and the cell numbers were slowly decreasing. The FACS 
analysis of dead cells, shown by Sub-G1 fraction, also revealed that MYCN-high 
cells were more sensitive to death when compared to MYCN-low cells. However, 
when MYCN-high cells regrew after chemotherapy the cell death rates decreased 
and were compared to those of untreated cells, Figure 9C. The MYCN-low cells, 
however, continued to slowly increase the proportion of dead cells. 
Visualizing the proliferating cells using EdU staining showed that after drug removal 
MYCN-low cells were not able to escape the cell cycle arrest obtained during 
treatment, Figure 9D. In contrast, a proportion of treatment-arrested MYCN-high 
cells were able to resume the cell cycle within less than three days after DOX 
washout. The proportion of proliferating cells was increasing with the longer 
incubation of cells in drug-free medium.  
Additionally, the expression of Ki67 protein, which is known to be present only in 
proliferating cells, was investigated. Untreated MYCN-low and MYCN-high cells 
were positive for Ki67 immunostaining, however during treatment the Ki67 
expression disappeared suggesting that cells were not proliferating, Figure 10. After 
treatment, as already expected, MYCN-low cells remained Ki67-negative as 
expected, whereas regrown MYCN-high cells reestablished Ki67 expression.  
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Figure 9. MYCN sensitizes cells to chemotherapy-induced death and drives cellular regrowth 
after chemotherapy. A Experimental approach: cells were pre-incubated with +/- doxycycline to 
obtain MYCN-low and MYCN-high status and treated with 0.1µg/ml DOX for 72h. After treatment 
DOX was washed out and cells were subsequently incubated in drug-free medium for indicated time 
points. B Relative cells numbers of population dynamics captured by live-cell imaging. MYCN-low 
and MYCN-high populations treaded with DOX for 72h and subsequently incubated in drug-free 
medium. Cells were imaged every 20 min. Grey area indicates time of DOX treatment. Mean ±SD, 
n=2. C Cell death measured by gating Sub-G1 fraction from DNA content using FACS. Grey area 
indicates time of DOX treatment. Mean ±SEM, n=3 D Cell cycle progression of cells treated with 
DOX for 72h and subsequently incubated in drugs-free medium for 10 days. DNA synthesis (S-
phase) determined by EdU incorporation versus DNA content. n=3; a representative experiment is 
shown.  
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Taken together, MYCN sensitizes cells to death during and after chemotherapy. 
Nevertheless, the remaining cells are able to escape drug-induced cells cycle arrest 
and re-establish cell proliferation. Cells with low MYCN level stay arrested after 
chemotherapy.  
 
Figure 10. MYCN-high cells restore expression of proliferation marker Ki67 after DOX 
treatment. Cells were collected at indicated time points and immunostained with the Ki67 antibody 
following by fluorescent antibody. DAPI used as a nuclear marker. n=3; representative experiment is 
shown. 
 
3.2.3. MYCN rescues cells from chemotherapy induced cellular senescence 
Next, the phenotypical responses of cells during and after treatment were 
investigated. Live-cell imaging showed that during DOX treatment, when both 
MYCN-low and MYCN-high cells were arrested, the Cdt1 was overexpressed in G1 
and G2 cells cycle phases, Figure 11. After treatment the majority of MYCN-low 
cells stayed arrested. The arrested MYCN-low cells obtained certain morphological 
features, such as flattened shape and enlarged nuclei, which are the characteristics 
of senescent cells, Figure 11A. Indeed, staining of MYCN-low cells for the 
senescence marker, senescence associated β-Galactosidase (SA-β-Gal), revealed 
positive SA-β-Gal activity, Figure 12A. Interestingly, the proportion of cells positive 
for the SA-β-Gal marker increased continuously and 14 days post treatment more 
than 90% of cells were stained positive for senescence, and overexpressed Cdt1, 
Figure 12C, 11A.  
MYCN-high cells displayed greater phenotypic variability after DOX washout, 
Figure 11B. A fraction of cells died after treatment without entering the cell cycle. A 
subpopulation of the MYCN-high cells was able to resume the cell cycle within less 
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than three days after treatment wash out and entered mitosis. Most of these cells 
failed to correctly carry out the cytokinesis, which resulted in undivided cells with 
two nuclei or cells with fragmented nuclei. The multinuclear cells died soon after 
mitosis. A minority of cells could divide successfully into two normally looking 
daughter cells, which progressed in the cell cycle and gave birth to new cells. 
These properly dividing cells after treatment were named ‘resister’ cells.  
 
Figure 11. Different cell fates after treatment visualized by live-cell imaging. Live cell imaging 
of TET21N-Cdt1 treated with DOX for 72h and subsequently incubated in drug-free medium.  During 
treatment cells arrest and accumulate mCherry-hCdt in all cell cycle phases. Examples of cells in 1-
mitosis; 2-G1 phase; 3-G2 phase; 4-arrested cell; 5-dead cell after treatment; 6-multinuclear cell 
after failed cell division. 
Early after treatment, the majority of MYCN-high cells were positive for SA-β-Gal 
activity. Nevertheless, over the time the senescent population became diluted by 
the regrowing resisters, which looked phenotypically similar to the untreated cells. 
The resister cells had the same shape and nuclear size as cells before treatment, 
were negative for SA-β-Gal, and the Cdt1 was expressed only in G1 phase, Figure 
11B, 12B-D. 
Taken together, MYCN is required to escape chemotherapy-induce senescence 
through cell cycle re-entry. In a majority of cases, the cell cycle re-entry sensitized 
cells to death after mitosis, but in very few cases MYCN-driven cells were able to 
proliferate successful after treatment. 
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Figure 12. MYCN rescues cells from chemotherapy induced cellular senescence. A, B 
Senescence associated β-Galactosidase (SA-β-Gal) staining of MYCN-low (B) and MYCN-high cells 
at different time-points after DOX treatment. DAPI used as a nuclear marker. n=3; representative 
experiment is shown. C Quantification of SA-β-Gal positive cells. Analysis was performed by FIJI 
software, Mean ± SD, n=2. D Changes of average population nuclear radii sizes in 
TET21N_Geminin_53BP1 cells after DOX treatment. Sells were segmented according to nuclear 
expression of 53BP1 and nuclear radii were analyzed by FIJI. Grey area indicates time of DOX 
treatment. Shadow areas represent population deviations. 
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3.2.4. MYCN-driven regrowth is clonal and not heritable 
To better characterize the resister cells their properties of regrowth were analyzed. 
It was observed that after DOX treatment MYCN-low cells looked untighten and 
homologously distributed in the cell culture dishes, whereas regrown MYCN-high 
cells were concentrating in dense colonies, Figure 13A. The analysis of 
clonogenicity showed that MYCN-low cells were not able to build sufficient colonies 
after treatment, Figure 13B. In contrast, MYCN-high cell showed clonal regrowth 
and the colonies were growing over time. 
Next, it was tested whether the MYCN-driven cellular regrowth can also be 
observed in MYCN-amplified cell lines. Two cell lines IMR5/75 and IMR32 with 
shRNA against MYCN were used and the regrowth after three different DOX 
concentrations was tested. In general, MYCN-amplified cell lines are more sensitive 
to DOX chemotherapy, therefore after treatment with 0.1 µg/mL DOX almost all 
cells were died and only a few colonies in MYCN-high IMR5/75 cells were 
observed, Figure 13C.  After treatment with 0.05 µg/mL DOX the IMR5/75 and 
IMR32 cells showed clonal regrowth at MYCN-high conditions and no regrowth was 
observed at MYCN-low conditions, Figure 13C,D. The reduction of DOX 
concentration to the very low level, 0.025 µg/mL, resulted in regrowth of both 
MYCN-low and MYCN-high cells but the colonies with MYCN were growing much 
faster as compared to cells without MYCN.  
To investigate whether the therapy selected for genetically distinct subpopulations 
that are immune to DOX, resister cells were characterized more closely. The 
growth rates of the resister and untreated cells were found to be similar, Figure 
14A. Exposing the resister cells to a second treatment with DOX resulted again in 
clonal regrowth with a comparable number of colonies as after the first treatment, 
Figure 14B. Thus, resister cells showed the same probability to regrow as the 
untreated population.  
Thus, for all tested cell lines the regrowth was MYCN-dependent and clonal, 
suggesting that only a small fraction of cells resisted therapy. Importantly, resister 
cells did not have a higher probability to survive subsequent treatment pulses 
indicating that non-genetic heterogeneity rather than selection of genetic 
subpopulations was responsible for resistance.  
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Figure 13. Clonal regrowth of MYCN-high cells. A 106 TET21N MYCN-low or MYCN-high cells 
were seeded in 10cm2  dishes and treated with 0.1µg/ml DOX for 72h. 9 days after treatment cells 
were fixed with 4% PFA, stained with methylene blue and imaged. B MYCN-low and MYCN-high 
cells were treated with 0.1µg/ml DOX for 72h, after treatment 10000 cells were reseed into 6-well 
plates. After indicated period of time colonies were fixed with 4% PFA, stained with methylene blue 
and imaged. The number of colonies was counted using FIJI’s particle analyzer. IMR5/75 (C) and 
IMR32 (D) cells were treated with three different DOX concentrations for 24 hours. Staining and 
quantification of colonies was performed 14 days after reseeding with the same protocol as in B. 
Mean ±SEM, n=3 
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Figure 14. Regrowth of MYCN-high cells is not heritable. A Growth kinetics of untreated and 
resister cells. Resister cells, which survived first treatment with DOX, were incubated for one week in 
the cell culture. The growth rate of resister cells was compared with the growth rate of untreated 
cells by counting the number of cells with MACSQuant analyzer, Mean ±SEM, n=3. B Cells were 
treated with DOX for 24h and 10000 cells were reseeded into 6-well plates. Untreated = without 
DOX treatment, 1.DOX= first time treatment with DOX, 2.DOX= resister cells which regrown after 
first DOX treatment were treated second time with DOX. 9 days after treatment cells were fixed with 
4% PFA, stained with methylene blue and imaged. The number of colonies was counted using FIJI’s 
particle analyzer. Mean ±SEM, n=3. 
 
3.3. Molecular response to DNA damage  
3.3.1. Doxorubicin treatment activates p53 signaling and suppresses cell 
cycle genes 
To explore the role of MYCN on the molecular responses of cells during 
chemotherapy, proteins and mRNA involved into DNA damage, cell death and cell 
cycle signaling were analyzed. The DNA damage response pathway was activated 
during DOX treatment as indicated by the increase of p53 protein and its targets, 
Figure 15A. In line with a higher cell death rate observed in MYCN-high cells, p53 
mRNA and protein were more strongly expressed in untreated and DOX treated 
MYCN-high compared to MYCN-low cells. The p53 protein levels increased as 
early as 3 hours after treatment, achieved maximum 9 hours after treatment and 
started to decline after 18 hours. The p53 mRNA expression was not affected by 
DOX and stayed constant during the treatment period, suggesting that after DNA 
damage p53 is regulated on the translational level. The p53 endogenous targets 
MDM2 and p21 increased significantly 6 hours after treatment. MDM2 protein was  
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Figure 15. Doxorubicin treatment activates p53 signaling and suppresses cell cycle genes. A 
Expression of proteins involved in p53 pathway. TET21N Cells were harvested at indicated time 
points after DOX treatment and lysates were analyzed by western blot. n=3. Representative 
experiment is shown. B Expression of genes involved in p53 and Rb/E2F1 pathways. Cells were 
harvested at indicated time points after DOX treatment. RNA was extracted, reversely transcribed 
and expression of genes was quantified via qRT-PCR. Mean ±SEM, n=3 
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more highly expressed in MYCN-high cells, whereas p21 protein and mRNA 
expression was comparable in MYCN-low and MYCN-high cells. Further p53 
targets, BAX and PUMA, involved in apoptotic signaling, were more highly activated 
in MYCN-high cells, Figure 15B. Genes involved in cell cycle regulation e.g. E2F1, 
SKP2, CCNA2, CCNE1 were more highly expressed in untreated MYCN-high cells 
compared to untreated MYCN-low cells. During treatment the expression of the cell 
cycle genes was strongly reduced for both MYCN conditions, which is consistent 
with observed cell cycle arrest and activation of p21 during DOX treatment. The 
expression of CCND1 continuously increased in MYCN-high cells continuously 
during treatment. 
Thus, during DNA damage TET21N cells activate p53 signaling and downregulate 
genes responsible for proliferation. MYCN enhances p53 expression, which leads 
to higher expression of p53 targets genes. However, despite elevated p53 
activation in MYCN-high cells, the levels of the cell cycle suppressor p21 were 
similar to those of MYCN-low cells, suggesting that MYCN suppresses p21 
expression.  
 
3.3.2. MYCN-high resister cells overcome transient p53-p21 activation 
Phenotypically resister cells displayed the same behavior as untreated cells and 
appeared to reestablish the untreated population. Therefore, it was analyzed 
whether resister cells share the same molecular expression patterns as untreated 
cells. To this end, the activation status of p53 signaling after DOX washout was 
investigated. The activity of p53 signaling was monitored by its phosphorylation on 
serine 15 (Ser15) and expression of p21 protein, Figure 15. It was confirmed that 
p53 signaling was activated during treatment, but after DOX removal MYCN-high 
and MYCN-low cells displayed different molecular responses. In the senescent 
MYCN-low cells, p53 phosphorylation and p21 expression remained elevated even 
after drug removal. In contrast, in MYCN-high cells the continuous decrease of p53 
phosphorylation and p21 expression was observed, and 14 days after treatment the 
expression of these proteins was as low as in the untreated cells. 
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Figure 16. Resister cells recover pre-treatment pP53 (Ser15) and p21 expression. A 
Expression of p53 protein phosphorylated at Ser15 B Expression of p21 protein during and after 
DOX treatment. Cells were collected at indicated time points, fixed, and stained with conjugated 
antibodies. The protein intensity versus DNA content was measured by FACS and analyzed by 
FlowJo. n=3; a representative experiment is shown . C Medium intensities of p53 phosphorylated at 
Ser15 and p21 levels measured in A. Mean ±SEM, n=3.  
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While it is possible that all MYCN-high cells reduced their p53 signaling, it is more 
likely that this reduction was a result of the observed changes in the composition of 
the population over time (see Figure 11, 12). Early after treatment the culture was 
dominated by senescent cells, which were diluted by regrown resister cells that 
took over the population.  
 
3.3.3. MYCN causes full recovery of transcriptome after therapy 
To analyze the cellular responses on the global level, the RNA-Seq of cells before, 
during and treatment was performed. The analysis of global transcriptome revealed 
similar dynamics as were observed for the DNA damage response, Figure 17A. 
MYCN-low cells during and after treatment clustered together, separately from 
untreated cells, suggesting that senescent cells maintained the treatment-induced 
expression profile even after drug removal. The transcriptome of MYCN-high cells 
changed during treatment but returned to the untreated cells over time-course after 
treatment. Again, this could be explained by continuous domination of resister cell 
in the population. 
 
Figure 17. MYCN causes full recovery of transcriptome after DNA damage. A Principal 
component analysis of whole-genome RNA-Seq data of TET21N cells treated with DOX. Arrows 
highlight the changes in expression during and after treatment. Cells were harvested, RNA was 
isolated and libraries for RNA-Seq were prepared and sequenced on Illumina platform. Two 
biological replicates are shown. B Gene ontology enrichment terms (p<0.05) of genes showing 
significant differences in the likelihood-ratio test in response to doxorubicin treatment between 
MYCN-low and MYCN-high TET21N cells. 
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Furthermore, 2831 genes showing significant difference between MYCN-high and 
MYCN-low cells in over the time course were identified via likelihood ratio test. 
Gene ontology analysis revealed that the identified genes were most highly 
enriched in the cell cycle, DNA damage response and DNA damage repair 
pathways, Figure 17B.  
 
Figure 18. DNA damage and cell cycle pathways are differently activated in resister and 
senescent cells. RNA-Seq expression of selected genes which show different response to DOX 
treatment between MYCN-low and MYCN-high populations. Mean ±SEM, n=2. 
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Examples of selected genes demonstrate that DNA damage response was 
completely inactivated in MYCN-high cells after regrowth and stay active in 
senescent cells, Figure18. As expected, MDM2 expression stays elevated in 
senescent cells, indicating active p53 signaling. CDN1A and GADD45A, both p53 
target genes and markers for cells cycle arrest, stay highly expressed in MYCN-low 
senescent cells. Expression of BAX in MYCN-low cells was reduced after 
treatment, suggesting that senescent cells are not sensitive to apoptosis. Cell cycle 
genes demonstrated that the cell cycle machinery shuts down during treatment and 
completely recovers after treatment only in MYCN-high cells. This was true for 
genes involved in G1/S and G2/M transitions. Interestingly, the expression of 
CCND1 was highly upregulated in MYCN-low senescent cells, in line with previous 
reports on senescence (Atadja et al., 1995; Fukami et al., 1995; Lucibello et al., 
1993).  Whereas in MYCN-high cells the CCND1 level was first upregulated but 
when the resister cells dominated the population CCND1 expression decreased to 
the level of untreated cells.  
 
3.3.4. MYCN causes full recovery of epigenome after therapy 
In addition to genetic changes, the treatment-induced dynamics of epigenetic 
histone modifications were investigated using ChIP-Seq. The analysis of histone 
modifications, known to mark active promoters (H3K4me3), Polycomb repressive 
complex 2-related gene silencing (H3K27me3), and DNA methylation (H3K9me3) 
was performed. It was found that the read density in these three epigenetic markers 
decreased during DOX treatment in both MYCN-low and MYCN-high cells, 
Figure19A. After treatment MYCN-low senescent cells kept low read density for 
H3K4me3 and numbers of reads for H3K27me3 and H3K9me3 decreased even 
stronger over time. In MYCN-high cells the read density of all modified histones 
was recovered to the same or even higher levels. Among these three epigenetic 
modifications, H3K4me3 demonstrated a recovered read density as early as three 
days after DOX washout, which may suggest its key role in cell regrowth.  
Interestingly, it was found that the expression of histone-specific methyltransferases 
and demethylases correlated with epigenetic patterns and was in agreement with 
the reports about cellular senescence, Figure 19B. The loss of methyltransferase 
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DPY30 and overexpression of demethylase KDM5B, which are both H3K4me3 
specific, was observed in MYCN-low cells. H3K37me3 specific modifier, EZH2, was 
downregulated in MYCN-low senescent cells. KDM6B, a H3K27me3 specific 
demethylase, was upregulated in MYCN-low cells. The key methyltransferase for 
 
Figure 19. MYCN causes recovery of epigenetic histone marks after therapy. A Treatment 
induced changes in Chip-Seq occupancy of H3K4me3, H3K27me3 and H3K9me3. Cells were 
treated with DOX for 72h, harvested at indicate time points, fixed and chromatin-immunoprecipitated 
with antibodies. DNA libraries were prepared and sequenced on the Illumina platform. Mean ±SEM, 
n=2. B RNA-Seq expression of regulators of histone modifications, Mean ±SEM, n=2. 
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H3K9me3, SUV39H1 was suppressed in senescent cells but upregulated in the 
resister cells, which correlate with the recovery of H3K9me3 signals. In contrast, 
KDM4B, the demethylase for H3K9me3, was elevated in senescent cells and 
repressed in resister cells.  
To summarize, for every molecular profile the studied MYCN-high resister cells re-
established the pre-treatment profile, including gene expression, protein, 
expression and epigenetic histone markers. Whereas the MYCN-low cells exhibited 
altered molecular profiles after treatment, which may contribute to induction and/or 
maintenance of the senescence phenotype. 
 
3.3.5. Regrowth after chemotherapy is MYCN and p21 dependent 
Upon untreated conditions, MYCN shortens the lengths of cell cycle phases and 
increases the proportion of cycling cells due to the activation of genes involved into 
the cell cycle progression and suppression of cell cycle inhibitor p21. It was 
hypothesized whether MYCN promotes escape from therapy-induced long-term 
arrest via the same mechanisms as cell cycle transition under normal growth 
conditions. Therefore it was tested whether regrowth after chemotherapy can be 
explained by MYCN mediated suppression of p21. 
 
Figure 20. p21 knockdown induces clonal regrowth after DOX treatment in TET21N MYCN-low 
cells. A Expression of MYCN, p53 and p21 proteins during and after DOX treatment in TET21N 
cells with stable expression of p21 shRNA  (p21 knockdown) and cells with scrambled shRNA (p21 
functional). B p21 shRNA cells show clonogenic regrowth in both MYCN-low and MYCN-high 
conditions. Cells were treated with 0.1µg/ml DOX for 72h, after treatment 10000 cells were reseed 
into 6-well plates. After 14 days colonies were fixed, stained with methylene blue and imaged. 
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Figure 21. p21 knockdown helps to escape chemotherapy-induced senescence. Senescence 
associated β-Galactosidase (SA-β-Gal) staining of TET21N p21 shRNA and scr shRNA cells. Cells 
were treated with DOX for 72h and subsequently incubated in drugs-free medium for 3 days. DAPI 
used as a nuclear marker. n=3; a representative experiment is shown. 
To test this hypothesis the TET21N cells stably expressing shRNA against p21 
were used. In these cells p53 signaling is activated by DOX treatment, as indicated 
by the increase of p53 level, but p21 protein expression stays low, Figure 20A. The 
colony formation assay revealed that MYCN-low cells with reduced p21 expression 
were able to build colonies and regrow after DOX treatment, while cells with 
functional p21 were not able to regrow, Figure 20B. Additionally, it was observed 
that MYCN-high cells lacking p21 built a higher number of colonies than cells with 
functional p21. 
Furthermore, it was found that p21 expression is crucial for induction and 
maintenance of drug-induced senescence after DOX treatment. 10 days after 
treatment MYCN-low cells with scr shRNA had, as expected, a flattened cell shape, 
enlarged nuclei and stained positive for SA-β-Gal, Figure 21. While the MYCN- low 
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cells with p21 shRNA, similar to MYCN-high cells, had the same shape and nuclear 
size as cells before treatment and were negative for SA-β-Gal.  
 
Figure 22. p21 knockdown suppresses G1 arrest and increases cell death during and after 
treatment. A Time course of cell cycle distributions in TET21N p21 shRNA cells during and after 
DOX treatment measured by FACS and analyzed by FlowJo. Mean  ±SD; n=3. B Cell cycle 
progression of TET21N cells treated with DOX for 72h and subsequently incubated in drugs-free 
medium for 3 days. DNA synthesis (S-phase) determined by EdU incorporation versus DNA content. 
n=2; a representative experiment is shown. C Cell death in TET21N p21shRNA cells measured by 
gating Sub-G1 fraction from DNA content using FACS. Mean ±SEM, n=3. Grey area indicates time 
of DOX treatment. 
Next, it was analyzed how p21 knockdown influences cell cycle arrest during and 
after DOX treatment. Distribution of cell cycle phases measured by FACS revealed 
that G1/S transition was affected in both MYCN-low and MYCN-high cells. 24h after 
treatment cells reduced the fraction of G1 and S cells and arrested predominantly in 
G2 phase, Figure 22A. However, already 3 days after treatment proportions of cells 
in G1 and S phases increased, while those in G2 phase decreased, suggesting that 
cells escaped cell cycle arrest and started cycling again. The reduction of cells in 
G1 phase during treatment suggests that p21 is required for the activation of G1 
arrest whereas G2 arrest can be maintained without p21 activation. Additionally the 
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proportion of proliferating cells was visualized using EdU incorporation. Again, 72h 
after DOX treatment cells were mostly arrested in G2 phase, however, already 
three days after DOX washout 4.5% of MYCN-low and 21% of MYCN-high cells 
entered S-phase. Notably, 3 days after DOX washout a higher fraction of p21 
knockdown MYCN-high cells entered S-phase when compared to cells with active 
p21 (compare Figures 9D and 22B). 
Interestingly, MYCN-low and MYCN-high cells showed similar dynamics in cell 
death, Figure 22C. The proportion of dead cells increased during treatment and 
continued to increase up to 3 days after treatment. When normally dividing resister 
cells started to dominate the population the fraction of dead cells decreased. The 
results demonstrate that lowering the p21 level sensitizes cells to apoptosis.  
Thus, it was shown hat regrowth after chemotherapy depends on p21 expression. 
 
3.3.6. Switching the MYCN conditional expression after treatment influences 
cellular regrowth 
To confirm that the regulation of p21 is mediated via MYCN, the conditional MYCN 
expression in TET21N was taken in advantage. For this, MYCN-low and MYCN-
high cells were treated with DOX for 72 hours and at the treatment washout the 
conditional MYCN expression was switched by adding or removing doxycycline. 
Cells were analyzed 16 days after switching MYCN status.  
Cells, which expressed low MYCN levels during treatment and high levels after 
treatment showed a regrowth potential similar to those of cells with continuously 
high MYCN expression, Figure 23A compare to Figure 9D. In contrast, cells, which 
expressed high MYCN levels during treatment and low MYCN levels after treatment 
reduced potential to proliferate. Staining for senescence confirmed the results 
obtained by cell cycle analysis, Figure 23B. It was found that the majority of cells 
that were MYCN-low during and MYCN-high after treatment were able to escape 
senescence. Whereas MYCN-high cells during and low after treatment had a high 
proportion of senescent cells.  
The p21 protein expression level was consistent with observed cellular phenotypes. 
Cells, which were MYCN-low during and MYCN-high after treatment had reduced 
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p21 expression and p21 protein levels were similar to resister cells with 
continuously high MYCN expression, Figure 23C, D, compared to Figure 16B. 
While cells, which were MYCN-high during and MYCN-low after treatment showed 
elevated p21 expression with p21 levels comparable to MYCN-low senescent cells.  
Taken together, MYCN strongly enhances the regrowth probability of cells after 
chemotherapy primarily by repressing p21 expression after treatment washout. 
 
Figure 23. Switching the MYCN conditional expression in TET21N cells after treatment 
influences cellular regrowth. MYCN-low and MYCN-high cells were treated for 72h with DOX. 
During DOX washout MYCN expression was switched by removing doxycycline from the media or 
by adding doxycycline to the media. 16 days after DOX treatment cells were analyzed. A Cells were 
stained by EdU; DNA synthesis was measured by FACS. B Cells were stained with SA-β-Gal assay 
and imaged (10x objective is used). C Cells were collected, fixed and stained with p21 fluorescein-
conjugated antibody. The p21 protein intensity was measured by FACS and analyzed by FlowJo. D 
Median intensities of p21 protein measured in C, n=2 to 3; representative experiments are shown. 
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3.4. Resister cells arise from G1-arrested subpopulation with an efficient DNA-
damage repair response 
3.4.1. High Cdt1 expression in G2 phase correlates with low Skp2 levels. 
Live cell imaging performed on TET21N_Cdt1 cells revealed that in normally 
cycling cells hCdt expressed only during G1 cell cycle phase, whereas cells 
arrested during DNA damage exhibited strong Cdt1 expression also in G2 phase, 
Figure 11. Another FUCCI marker, Geminin, was also deregulated after cell cycle 
arrest. Normally, Geminin is expressed only in S, G2 and M cell cycle phases; 
however after DOX treatment all cells lost Geminin expression. To explain and to 
understand this unspecific expression change of FUCCI markers the levels of Skp2 
protein, which is the regulator of Cdt1 and Geminin, were analyzed. 
The Cdt1 FUCCI construct contains a CY motif (aa 68-70), which is recognized by 
Skp2 and targeted for proteasomal-mediated degradation in the S and G2 cell cycle 
phases. In fact, staining for Skp2 protein in normally cycling cells revealed that 
Skp2 and Cdt1 expression were mutually exclusive, Figure 24A. Skp2 was low 
expressed in G1 cell cycle phase, accumulated in S phase and highly expressed in 
G2 phase, while high Cdt1 expression was observed in G1 cells.  
The results obtained with qPCR and RNA-Seq indicated that Skp2 expression was 
highly reduced during DOX treatment, probably due to the loss of its activator 
E2F1. Therefore, it was tested whether the loss of Skp2 expression can lead to 
Cdt1 accumulation. For this, the cell cycle restricted expression of Skp2 and Cdt1 in 
G1 and G2/S cell cycle phases were analyzed over the time course during and after 
treatment. The expression of the Skp2 protein and Cdt1 reporter were measured by 
FACS, and quantification of expression levels are shown in Figure 24B. MYCN-low 
and MYCN-high G1 phase cells maintained low Skp2 expression level over all 
analyzed time points. Cdt1 expression in G1 cells increased slightly during DOX 
treatment and decreased to the untreated levels in regrowing MYCN-high cells, 
whereas in senescent MYCN-low cells Cdt1 stayed elevated. In MYCN-low G2 
cells, Skp2 decreased and Cdt1 strongly increased already 24h after treatment. 
Low Skp2 and high Cdt1 levels in G2 phase remained persistent in MYCN-low 
senescent cells. In contrast, MYCN-high G2 phase cells first reduced Skp2 and 
increased Cdt1 but after regrowth the levels of Skp2 and Cdt1 were returned to 
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those of untreated cells. The Skp2 and Cdt1 dynamics in MYCN-high cells can be 
explained by the domination of normally dividing resister cells in the population over 
time. 
Low Skp2 expression in arrested cells can also explain loss of the Geminin, as 
Skp2 indirectly regulates Geminin through suppression of APC, a negative 
regulator of Geminin.  
Taken together, the Cdt1 and Geminin expression are very strictly controlled by cell 
cycle proteins. During DNA damage expression of the majority of cell cycle 
regulating molecules is altered, which results in cell cycle arrest and altered 
expression of FUCCI markers. 
 
Figure 24. High Cdt1 expression after DOX treatment in all cell cycle phases due to the loss 
of Skp2 expression. A Untreated TET21N_Cdt1 cells were stained with Skp2 antibody and 
analyzed by FACS. Plotted Skp2 and Cdt1 intensities versus DNA content visualize changes in the 
expression level of both proteins in different cell cycle phases. Skp2 versus Cdt1 plots visualize 
mutually regulation of both. n=3; representative experiments are shown. B Skp2 and Cdt1 
expression in different cell cycle phases. Cells were harvested during and after DOX treatment fixed 
and stained with Skp2 antibody for FACS analysis. For DNA content cells were stained with Vio-
Blue. Median intensities of Skp2 and Cdt1 in G1 and S/G2 cells cycle phases were analyzed by 
FlowJo. Mean ±SEM, n=2. 
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3.4.2. Single cell classification based on treatment-dependent cell cycle 
dynamics  
Despite the deregulation of FUCCI markers during DOX treatment it was possible 
to analyze the phases of cell cycle arrest in single cells. It was found that the 
deregulation of Cdt1 and Geminin occurs mostly 20-24 hour after DOX adding. To 
this time G1/S and G2/M checkpoints were activated and both MYCN-high and 
therefore MYCN-low cells already established cell cycle arrest, Figure 8B,C. Hence, 
knowing the cell cycle phase of cells in the time period between 12 and 20 hours 
after DOX adding is sufficient to identify in which phase they were arrested. 
Thus, all single cells in the population could be classified according their cell-cycle 
phase immediately prior to treatment and their phase of cell-cycle arrest during 
treatment. According to these criteria four groups were identified: M/G1->G1 arrest, 
G1->S->G2 arrest, S/G2->G2 arrest and G2->M-G1arrest, Figure 25. 
 
Figure 25. Live-cell imaging using Cdt1 and Geminin cell cycle markers uncovers four groups 
with different kinds of treatment-dependent cell-cycle arrests. Different dynamics of Cdt1 and 
Geminin changes upon DOX treatment in single cells. Single cells were classified into four groups 
according to their cell-cycle phase immediately prior to treatment and their phase of cell-cycle arrest 
during treatment. Cell-cycle phases were detected by either Cdt1 (high in G1) or Geminin (high in 
S/G2/M) fluorescence intensity. During cell cycle arrest the expression of these markers becomes 
decoupled from the underlying cell-cycle stage, with Cdt1 increasing substantially and Geminin 
decreasing. The more detailed descriptions to the each group see in text. 
The M/earlyG1->G1 arrested group includes cells which were in M or early G1 
phase at the beginning of treatment (low Cdt1, high Geminin). During treatment 
they stayed in G1 (Cdt1 increases, Geminin decreases). After treatment they 
remained G1 phase arrested.   
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The G1->S/G2->G2 arrested group contains cells which were in G1 phase at the 
beginning of treatment (high Cdt1, low Geminin). Within a few hours of treatment, 
these cells entered S phase and then entered G2 phase (Cdt1 decreases, Geminin 
increases). Cells arrested in G2, but fluorescence expression switched to that of the 
arrested phenotype (high Cdt1, low Geminin). 
The S/G2->G2 arrested group, contains cells which were in S or early G2 phase at 
the moment of treatment (Cdt1 decreases, Geminin increases). Cells arrested in 
G2 during and after treatment, but fluorescence expression switched to that of the 
arrested phenotype (high Cdt1, low Geminin). 
The G2->M->G1 arrested group, includes cells which were in G2 phase at the 
beginning of treatment (Cdt1 low, Geminin high), but entered mitosis and divided 
within a few hours of DOX treatment (Cdt1 increases, Geminin decreases). Cells 
stay arrested in G1.  
 
3.4.3. Only G1 arrested cells have exclusive potential to regrow 
To better understand features that allow resister cells to regrow, the phenotypes 
and cell fates of cells imaged by live-cell imaging were analyzed. The time of DOX 
treatment was reduced to 20 hours, which helped to enrich the proportion of 
regrowing cells, Figure 26A. Since MYCN-low cells stayed mostly arrested and did 
not regrow after DOX washout, the further analysis was focused only on MYCN-
high cells.   
To investigate the importance of cell cycle phases on treatment-induced cell fate, 
the individual FUCCI cells were followed continuously before, during and after 
treatment. Single cells were classified into four groups according their cell cycle 
phase immediately prior to treatment and the phase in which they arrested, Figure 
25, 26B. The behavior of cells in each individual group after drug removal was 
monitored. For each group the percentage of cells that underwent death, mitosis or 
arrest was measured. Cells, which were in M/G1 before treatment and arrested in 
G1, had the lowest probability to die after drug removal and highest probability of 
entering mitosis and dividing successfully, Figure 26C. Cells in the other three 
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groups died frequently after treatment. The cells, which entered mitosis, could not 
successfully divide and died shortly after mitosis. 
 
Figure 26. Resister cells are exclusively arrested in G1. A Relative cell numbers of population 
dynamics in TET21N_Cdt1 cells captured by live-cell imaging. Cells were treated with DOX for 20h 
and subsequently incubated in drug-free medium. Images were taken every 15 min for 9 days. Grey 
area indicates time of DOX treatment. B Experimental approach: MYCN-high cells that survived 20h 
of DOX treatment were grouped into four groups according their cell cycle progression and arrest 
during the fist 20h of DOX treatment. The grouping was based on the changes in Cdt1 expression 
level before and during treatment (described in Figure 25). The fates of single cells after treatment 
were tracked in FIJI using MTrackJ plugin. C Cell death, mitotic entry and death following mitosis for 
each group. D Summary of (C). Percentage of cells in each group and their fates 8 days after 
treatment. Only G1 arrested cells had the potential to regrow. 
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In general, G1-arrested cells had a higher potential to escape treatment-induced 
cell cycle arrest compared to G2-arrested cells and entered mitosis earlier after 
drug removal. The cumulative percentage of cell fate decisions of each group 8 
days after drug removal is summarized in figure 26C. Strikingly, resister cells 
exclusively arose from cells, which were in M/G1 before treatment and arrested in 
G2 (M/G1->G1 group). 
 
Figure 27. Visualization of single cell tracks of resister and untreated cells. Grey box indicates 
time of DOX treatment. Red boxes indicate G1, and black boxes S/G2 phases of the cell cycle. 
White numbers in the black boxes mean the time of whole cell cycle length in hours. Time of cell 
cycle phases can be determined from Y-axis. Tree left: Resister cell arrested in G1 during 
treatment, however post treatment it escaped G1 arrest and after some time properly divided into 
two cells and gave birth to the clonal population. Tree right: example of cell cycle lengths and 
divisions for one untreated cell. 
Visualizing of the track from one resister cell shows how this cell gives birth to a 
population of cells, Figure 27. Thus, the resister cell was in early G1 at the 
beginning of treatment and arrested in G1. 8 hours after DOX washout the cell 
could escape G1 arrest, transited further in the cell cycle and divided correctly into 
two cells. Its daughter cells divided again and the colony of resister cells arose. 
Interestingly, the lengths of cell cycle phases in progeny of resister and in untreated 
cells were similar. This suggests that only the mother cell, arrested by DOX 
treatment, had extended cell cycle length but after its division, the normal cell cycle 
is reestablished in the daughter cells.  
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Figure 28. Probability of regrowth is cell cycle dependent. A Untreated or DOX treated G1-only, 
G2-only, or G1+G2 single TET21N_Cdt1 cells were sorted into 96-well plates using FACS-sorter. 
Sort gates are indicated as squares. B After sorting plates with single cells were incubated for 3 
weeks and subsequently stained with cell titer blue assay. Wells with medium stained purple were 
counted as colony positive and wells with medium stained blue were considered as colony negative. 
Arrows highlight wells in the plates where single cells regrew after DOX treatment. C Quantification 
of regrown single cells after sorting. Mean ±SEM, n=3. 
To confirm the microscopy results the colony forming potential of treatment-
arrested single cells was analyzed. Single G1 and/or G2 phase cells were sorted 
into 96-well plates by FACS sorting, Figure 28A. While in untreated cells the 
regrown colonies were observed from G1 and G2 sorted cells, only G1-arrested 
cells were able to form colonies after DOX treatment, Figure 27B, C. When the G1 
and G2 arrested single cells were sorted randomly into one plate, the number of 
colonies was reduced.  
Taken together, regrowth is driven by a small number of resister cells that originate 
from the subpopulation arrested in G1 during treatment. 
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3.4.4. 53BP1 is differently activated in MYCN-low and MYCN-high cells  
To better understand the features that allow MYCN-high G1-arrested cells to 
regrow, the DNA damage repair was investigated. DOX generates mainly double 
strand breaks (DSBs), which can be repaired by two pathways, non-homologous 
end-joining (NHEJ) and homologous recombination (HR). However, HR is specific 
to the G2 phase. Taking into account that resister cells arise from G1, the analysis 
was focused on DNA damage repair by NHEJ, a repair pathway employed 
throughout the cell cycle.  
To study the activation of NHEJ in single cells, a fluorescence reporter system 
based on the protein 53BP1, which promotes NHEJ-mediated double-strand break 
repair, was used. 53BP1 localizes to chromatin regions adjacent to DSBs in a short 
time after damage and forms foci that can be visualized by light microscopy. These 
foci can serve as markers for activation of NHEJ repair. The TET21N cells were 
stably transfected with a construct containing a fragment of human 53BP1 protein 
fused to mCherry. The 53BP1 foci, detected by fluorescent construct were 
completely co-localized with foci detected by 53BP1 antibody staining, Figure 29.  
 
 
Figure 29. 53PB1 foci accumulation and localization. TET21N_53BP1 cells were either untreated 
or DOX treated for 24h and immunostained with the 53BP1 antibody following by staining with 
Alexa-488 conjugated antibody. The localization of 53BP1 foci visualized by mCherry_53BP1 
reporter or by 53BP1 antibody staining was compared. DAPI used as a nuclear marker. 
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Figure 30. 53BP1 foci formation is differently activated in MYCN-high and MYCN-low cells. A 
TET21N cells expressing 53BP1 were fixed and stained with y-H2AX antibody following by staining 
with Alexa-405 conjugated antibody at indicated time points after DOX treatment. DAPI was used as 
a nuclear marker, n=3, representative cells are shown B Quantification of 53BP1 and yH2AX foci 
dynamics after DOX treatment in MYCN-low and MYCN-high cells. Shadowed areas indicate 
population’s distributions. C Correlations between 53BP1 and yH2AX foci localization in MYCN-low 
and MYC-high cells at selected time points after DOX treatment. 
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To analyze whether the amount of DOX-induced DSBs correlates with activation of 
NHEJ, the 53BP1 expressing cells were stained with, y-H2AX, a phosphorylated 
version of H2AX, Figure 30A. yH2AX forms foci at sites of DNA damage and these 
foci provide an indirect measurement of DSBs in cells. 53BP1 can bind to yH2AX 
foci and initiate DNA repair by NHEJ (Kleiner et al., 2015). It was found that MYCN-
low cells rapidly accumulate a high number of yH2AX foci, suggesting a high 
amount of DNA damage. However, these cells were not able to significantly 
activate 53BP1 foci formation over the complete treatment period, which may 
indicate reduced repair activation, Figure 30A, B. In contrast, in MYCN-high cells 
both 53BP1 and yH2AX foci accumulated at a high levels and showed similar 
dynamics after DNA damage. Additionally, the analysis of colocalization between 
53BP1 and yH2AX foci revealed no correlation of these both markers in MYCN-low 
cells and a strong correlation in MYCN-high cells for all analyzed time points, 
Figure 30C.  
Thus, both MYCN-low and MYCN-high cells accumulate high amounts of DNA 
damage after DOX treatment but only MYCN-high cells recruit 53BP1 to the 
damage sites and activate NHEJ repair.  
 
3.4.5. G1-arrested cells have effective DNA-damage response during 
treatment 
To follow the dynamics of 53BP1 foci in MYCN-high cells over time and to 
investigated whether the G1-resister cells vary in their repair from other cells the 
live-time imaging with TET21N cells expressing 53PB1 and Geminin was 
performed. It was observed that 53BP1 foci dynamics in individual cells showed a 
large heterogeneity in the foci numbers and the time of foci induction. Hence, 
imaged cells were grouped according to their cell cycle progression and average 
foci dynamics were analyzed for each group individually. Only cells from the M/G1-
>G1 group, which includes resister cells, showed a reduction in average foci 
numbers already during treatment, indicating early and efficient DNA-repair via the 
NHEJ pathway, Figure 31A. An example of a G1-arrested single cell indicates that 
after successful repair, the cell made G1/S transition and entered mitosis, Figure 
31B. In other groups, cells transitioned through S-phase and maintained very high 
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foci numbers after drug removal indicating a continued occupancy of NHEJ 
pathway and incomplete repair. Cells with high numbers of 53BP1 foci were not 
able to escape cell cycle arrest and either stayed arrested or died, Figure 31C,D. 
 
Figure 31. G1-arrested cells have effective DNA-damage response during treatment. A 
Average 53BP1 foci dynamics of cells grouped according to their cell cycle progression as indicated 
in the top left. Only the G1-arrested cells (in red) show a foci dynamic suggesting effective repair via 
the NHEJ pathway. B, C, D Three single cell 53BP1 foci tracks representing each of the groups 
shown in A. Cell cycle phases are indicated as bars above the tracks. Gray area indicates time of 
DOX treatment. The screenshots from analyzed cells are shown. Inside screenshots: T-the time 
after DOX adding, F-number of foci; G1-geminin level. 
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Taken together, the resister cells, which accumulate in a G1 arrested 
subpopulation, did not pass through S-phase during treatment, possibly sustaining 
less DOX-induced damage, and showed enhanced activity of the NHEJ repair. 
Thus, an important synergy between a genetic lesion, MYCN, and non-genetic 
heterogeneity which allows to escape chemotherapy was identified.  
 
3.5. Tailored combination therapy that targets specific properties of resister 
cells successfully abolishes regrowth 
3.5.1. Cell cycle synchronization reduces resisters 
Applying the obtained knowledge on to resister cells may help to improve first-line 
therapy by specifically targeting the properties of these resister cells. Resister cells 
were characterized by MYCN expression, G1 arrest and efficient DNA-damage 
repair. It was therefore hypothesized that depletion of the G1-population prior to 
treatment should abolish resister cells.  
To test this, cells were pre-treated for 20h with either DMSO or with inhibitor 
against CDK1, which reversibly arrests cells at the G2/M border of the cell cycle. 
Pre-treatment with CDK1 inhibitor resulted in decrease of the G1 phase from 70% 
to 49% in MYCN-low cells and from 40% to 16% in MYCN-high cells, Figure 32A. 
After the DMSO or CDK1 inhibitor were washed out cells were subsequently 
treated with either DOX only, or with DOX in combination with CDK1 inhibitor. 
MYCN-low cells underwent cell cycle arrest without regrowth under all treatment 
conditions, suggesting that cell cycle phase distribution in these cells does not 
influence treatment outcome, Figure 32B. Upon DOX treatment MYCN-high cells 
pre-treated with CDK1i had similar regrowth as cells pretreated with DMSO. Upon 
combined DOX plus CDK1 inhibitor treatment a higher rate of cell death was 
observed, which is in agreement with previous studies reporting that inhibition of 
CDK1 sensitizes MYCN-amplified cells to death (Chen et al., 2013). However, while 
delayed, regrowth was not completely abolished in these cells.  
Live-cell imaging of cells pretreated with CDK1 inhibitor and subsequently treated 
with DOX plus CDK1 inhibitor revealed that resister cells originated from a small but 
persistent G1 subpopulation, Figure 32C. 
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Figure 32. Combined treatment with CDK1 inhibitor reduces but not abolishes resisters. A 
Cell cycle distribution of untreated cells (control) or cells treated with 7µM CDK1 inhibitor RO-3306 
for 24h. Cell cycle was measured by FACS and analyzed by FlowJo. Mean ±SEM, n=3. B 
Comparison of cellular regrowth. Cells were pretreated with either DMSO or with CDK1 inhibitor. 20h 
after pretreatment CDK1 inhibitor was washed out and cells were treated with either DOX alone or 
with DOX+CDK1i. Cell numbers were counted with FACS. Mean ±SEM, n=2. C Live cell imaging of 
TET21N_Cdt cells. During pretreatment with CDK1 inhibitor cells mostly arrested in G2 phase (cells 
without nuclear marker). But a small fraction of cells stayed in G1 phase (cells with red nuclear 
marker). One G1-arreted resister cell (indicated by white arrow) regrew and gave birth to a colony of 
cells. 
Additionally, cellular regrowth in cells pretreated with CDK4 inhibitor was 
investigated. Inhibition of CDK4 activates G1 cell cycle arrest through decrease of 
Rb phosphorylation. Thus, after pretreatment with CDK4 inhibitor for 20h 98% of 
MYCN-low and 85% of MYCN-high cells were accumulated in G1 phase Figure 
32A. It was hypothesized that accumulation of cells in G1 phase should enrich the 
number of regrowing cells after DOX treatment. The same treatment conditions as 
for CDK1 inhibitor were applied. As expected, MYCN-low cells arrested and 
maintained the same cell numbers irrespective of treatment conditions, Figure 33B. 
MYCN-high cells, despite high proportion of G1 cells, exhibited reduced regrowth. 
Low regrowth rate of cells enriched in G1 may indicate that inhibition of CDK4 
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suppresses important players responsible for G1/S transition and through this 
CDK4 inhibition can delay but not abolish regrowth.  
 
Figure 33. CDK4 inhibitor reduces regrowth. A Cell cycle distribution in untreated cells (control) 
or cells treated with 4µM CDK4 inhibitor LEE011 for 24h. Cell cycle was measured by FACS and 
analyzed by FlowJo. Mean ±SEM, n=3. B Comparison of cellular regrowth. Cells were pretreated 
with either DMSO or CDK4 inhibitor. 24h after pretreatment CDK4 inhibitor was washed out and 
cells were treated with either DOX alone or with DOX+CDK4 inhibitor. Cells were counted with 
FACS. Mean ±SEM, n=2. 
To summarize, already a single resister cell is sufficient for relapse. Since even in 
vitro it is impossible to achieve a complete synchronization, this strategy, although 
good in theory is unlikely to be effective in the clinic.  
 
3.5.2. AMT inhibition during DNA damage completely prevents regrowth of 
resister cells  
Since the synchronization of the cell cycle cannot completely abolish regrowth after 
chemotherapy, the second property of resister cells, DNA-damage repair was 
targeted. The activation of DSBs leads primarily to activation of ATM-Chk2 kinases, 
but ATR-Chk1 kinases, which primarily respond to single strand breaks, can also 
be activated by DSBs. Inhibitors against these kinases in combination with DOX 
were tested, Figure 34. It was found that after combined treatment with DOX and 
ATM inhibitor for 24h the numbers of MYCN-high cells declined rapidly and 
regrowth was completely abolished, Figure 34B. Whereas MYCN-low cells were 
just slightly affected by ATMi, and s majority of the cells stayed arrested. The Chk1 
inhibitor strongly reduced regrowth of MYCN-high cells, however few resister cells 
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survived and started to grow again, Figure 34E. The ART inhibitor and combined 
inhibitor against Chk1&Chk2 were less effective, the regrowth of MYCN-high cells 
was delayed compared to DOX only treatment but still a high fraction of cell regrew, 
Figure 34 C,D.  
 
Figure 34. Comparison of regrowth after combined treatment of DOX together with DNA 
damage repair inhibitors. A Cells were treated with DOX for 24h and subsequently incubated in 
drugs-free medium. At indicated time points cells were collected and counted with FACS. Mean 
±SEM, n=3. B Same as in A, except DOX was used in combination with 10 µM ATM inhibitor KU-
60019, n=3. C DOX was used in combination with 5 µM ATR inhibitor VE821, n=3. D DOX was used 
in combination with 300 nM Chk1&Chk2 inhibitor AZD7762, n=2. D DOX was used in combination 
with 3 µM Chk1 inhibitor LY2603618, n=2. 
Thus, from all inhibitors tested, only combined therapy with DOX and ATM inhibitor 
was sufficient to abrogate regrowth of resister cells. ATM is a key regulator of DNA 
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damage repair and promotes NHEJ by recruiting 53BP1 to the damaged sites. 
Therefore, it was tested whether treatment with ATM inhibitor impairs the activation 
of 53BP1 foci formation in MYCN-high cells during treatment. In line with the results 
from figure 33B, live-cell imaging confirmed that under combined treatment with 
DOX and ATM inhibitor cells were continuously dying and not regrowing, Figure 35. 
As expected, inhibition of ATM during DNA damage strongly decreased the number 
of 53BP foci, suggesting inhibition of NHEJ during DNA damage. Geminin levels 
decreased after both treatment conditions suggesting cell cycle arrest, and started 
to increase again only in regrowing resister cells which were treated with DOX only. 
Interestingly, Geminin decrease in cells treated with DOX plus ATMi was delayed 
compared to DOX only treated cells, hinting that ATMi impairs cell cycle arrest. 
The strong regrowth abolishing effect of combined treatment with DOX and ATM 
inhibitor was confirmed on several MYCN-tunable cells lines, Figure 36. Thus, two 
MYCN-overexpressing and two MYCN-amplifying cells lines treated for 24h with 
DOX were not able to build colonies after combination therapy, whereas a large 
number of colonies arose after treatment with DOX only.  
 
Figure 35. Inhibition of ATM abolishes regrowth and suppresses 53BP1 foci formation. 
Quantification of live-cell imaging of MYCN-high TET21N_Geminin_53BP1 cells treated either with 
DOX alone or with DOX plus ATM inhibitor. The quantified relative cell numbers, average foci 
numbers and Geminin intensities of populations are shown.  
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Figure 36. Combined treatment with DOX plus ATM inhibitor prevents regrowth in all tested 
cell lines. Two cell lines with transgenic inducible MYCN and two MYCN-amplified cells lines were 
treated for 24h either with DOX alone or with DOX and ATM inhibitor. 14 days after treatment cells 
were fixed, stained with methylene blue and colonies were imaged. 
To summarize, the enhanced repair ability of G1 arrested cells allows some cells to 
successfully repair, recover and regrow. It was shown that suppression of DNA 
DSB repair combined with DNA damage induction completely abolishes resister 
cells. 
 
3.5.3. Inhibition of ATM suppresses p53 signaling after DNA damage and 
impairs G1 checkpoint. 
To better understand mechanisms by which inhibition of ATM upon DNA damage 
prevents regrowth, the activation of p53 signaling and cell cycle arrest during 
combined treatment were analyzed.  
It was found that cells treated with DOX and ATMi failed to autophosphorylate ATM 
at Ser1981, Figure 37A. This autophosphorylation is essential for the activation of 
ATM. As a result, upon combined treatment p53 signaling stayed inactive, indicated 
by low p53 Ser15 phosphorylation and the absence of p21 activation, Figure 37B,C. 
Notably, 24 hours after treatment MYCN-high cells managed to increase p53 
activity and p21 expression, suggesting that in absence of ATM other kinases, i.e. 
ATR or DNA-PK, could phosphorylate p53. 
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Figure 37. ATM inhibitor suppresses p53 signaling after DOX treatment. A Expression of ATM 
protein phosphorylated at Ser1981. Cells were treated either with DOX alone or with DOX plus ATM 
inhibitor for 24h. Cells were collected at indicated time points, fixed, and stained with fluorescein-
conjugated antibodies and measured by FACS. Medium intensities of pATM (Ser1981) are plotted. 
Mean ±SEM, n=3. B Same as in A, except p53 protein phosphorylated at Ser15 was measured. C 
Same as in A, except p21 protein expression was measured. 
Analysis of the cell cycle revealed that upon combined treatment cells had delayed 
cell cycle arrest, as shown by disappearing of S-phase only 24 hours after 
treatment, Figure 38A,B. Activation of cell cycle arrest was temporally in line with 
the increase of p53 phosphorylation and p21 expression in DOX and ATM inhibitor 
treated cells. Interestingly, MYCN-high cells were arrested predominantly in G2 
phase, indicating that inhibition of ATM impairs G1/S cell cycle checkpoint and 
more cells transit through S phase before arrest. 7 days after treatment, only a 
small number of MYCN-high cell left, as they were continuously dying after 
treatment, whereas MYCN-low cells stayed arrested, Figure 38C. 
Taken together, inhibition of ATM upon DNA damage leads to the suppression of 
p53 activation and delayed cell cycle arrest, which means that damaged cells move 
through S and M phases and accumulate even more damage. Together with the 
reduced activation of NHEJ repair this leads to the cell death and results in 
complete elimination of G1 resister cells.  
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Figure 38. ATM inhibition during DNA damage impairs G1 cell cycle checkpoint. A Cell cycle 
progression of cells treated with DOX and ATM inhibitor for 24h and subsequently incubated in drug-
free medium. DNA content was measured by FACS. n=3; a representative experiment is shown. B 
Time-course of cell cycle distributions of cells treated as in A. Cell cycle is analyzed by FlowJo. 
Mean ±SD; n=3. C Cell death measured by gating Sub-G1 fraction from DNA content using FACS. 
Mean ±SEM, n=3.  
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4.  Discussion 
4.1.1. MYCN accelerates cell cycle progression under normal conditions and 
impairs cell cycle arrest during DNA damage 
The role of MYCN on the cell cycle and response to chemotherapy was 
investigated in well-established MYCN tunable, p53 wild type neuroblastoma cell 
lines. The conditional MYCN overexpression in TET21N cells was sufficient to 
reduce the duration of G1 phase and to accelerate cell proliferation, Figure 6C,E 
(Lutz et al., 1996; Muth et al., 2010). Conversely, reduction of MYCN expression in 
MYCN-amplified IMR5/75 cell line resulted in the increase of the proportion of cells 
in G1 and reduction of proliferating cells in S, Figure 6D.  
Analysis of FUCCI fluorescence sensors, Cdt1 and Geminin, in cells imaged by 
time-lapse microscopy allows to calculate the total cell cycle lengths and the 
duration of cell cycle phases (Sakaue-Sawano et al., 2008). In TET21N cells MYCN 
overexpression leads to the reduced overall cell cycle time achieved mostly by 
shortening of G1, Figure 7. The results of live-cell imaging analysis are in 
agreement with the original study on TET21N cells, which found that MYCN 
expression shortens time to needed progress through the cell cycle, specifically 
shortening the G1 phase (Lutz et al., 1996).  
In the present study one of the most widely used chemotherapeutic agents, 
Doxorubicin (DOX), was used to analyze the role of MYCN on cellular regrowth 
after treatment. Doxorubicin is a well-known topoisomerase II inhibitor, generating 
DSBs, but also inhibiting DNA and RNA synthesis and producing single stranded 
breaks (Dees et al., 2008; LoConte et al., 2008). DNA damage, induced by DOX, 
resulted in the arrest of both MYCN-low and MYCN-high cells at G1 and G2 phases 
of the cell cycle. However, the activation of cell cycle checkpoints was established 
only 2-10 hours after induction of DNA damage. These findings are in line with 
previous observations, which showed that G1/S and G2/M cell cycle checkpoints 
are not fully initiated until several hours post irradiation (Deckbar et al., 2010; 
Krempler et al., 2007; Linke et al., 1997; Lobrich and Jeggo, 2007; Syljuasen, 
2007). This implies that many cells with unrepaired DBSs enter S and M phases, 
which leads to the accumulation of additional damage (Linke et al., 1997). DNA 
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damage is particularly harmful in S and M phases of the cell cycle. During S phase, 
DNA damage interferes with the replication fork progression and base damages 
lead to base mispairing resulting in point mutational changes (Deckbar et al., 2011; 
Tercero and Diffley, 2001). Moreover, unrepaired DSBs and single strand breaks 
can lead to replication fork stalling or collapse, which can aggravate the damage 
causing further DSBs and chromosome breaks (Deckbar et al., 2011; Tercero and 
Diffley, 2001). During M phase, DNA damage can result in loss of genetic material 
leading to genetic alterations or even to the death of the daughter cells (Deckbar et 
al., 2011; Lobrich and Jeggo, 2007). Therefore, it is very critical for cells to have 
active checkpoint signaling to control cell cycle progression in the presence of DNA 
damage.  
Two major pathways, p53/p21 and Chk2/Cdc25, regulating checkpoint activation 
after DNA damage are known (Iliakis et al., 2003; Lukas et al., 2004). The former 
pathway mostly regulates the G1/S transition and involves the phosphorylation of 
p53 and its negative regulator MDM2 by ATM and Chk2 leading to p53 activation 
and stabilization (Kastan and Bartek, 2004; Kastan et al., 1992; Khosravi et al., 
1999). Thereafter p53 transcriptionally upregulates the expression of its target 
genes, of which p21 is essential for inhibiting G1/S entry (Bartek and Lukas, 2001; 
Sherr and Roberts, 1999). This pathway requires transcriptional activation following 
posttranslational modifications and therefore the full activation of this mechanism 
takes several hours. Additionally, under DNA damage p21 can also contribute to 
the G2/M checkpoint by p21-mediated degradation of the G2-associated Cyclin B1 
(Gillis et al., 2009). A second ATM dependent pathway, which regulates both G1/S 
and G2/M checkpoints is based on the ATM-dependent phosphorylation of Chk2. 
Activated Chk2 targets the phosphatase Cdc25A for rapid ubiquitylation and 
degradation.  This prevents the removal of inhibitory phosphates from CDK1/CDK2 
and leads to the cell cycle arrest (Mailand et al., 2000). This pathway is activated 
more rapidly because it involves only posttranslational modifications, such as 
phosphorylations and ubiquitylations. 
In this study, MYCN was found to delay activation of both cell cycle checkpoints for 
2 to 3 hours and to increase the proportion of transiting cells up to 25%, Figure 9. 
These findings raise two questions. First, why does it take several hours till 
complete cell cycle arrest and second, how can MYCN delay the cell cycle 
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checkpoint activation. One possible explanation of the first question is that p53 
mediated p21 activation is slow since it requires posttranslational modifications and 
transcriptional activation (Riley et al., 2008). In TET21N cells the significant 
activation of p21 mRNA and protein expression was observed only 6 hours after 
DOX addition. However after 6 hours of treatment still a high number of cells, 
especially MYCN-high cells, were able to enter S phase. The understanding of the 
concept of the restriction point is important for the explanation of how the cell cycle 
transitions work. The restriction point is defined as the time in G1 progression when 
Rb phosphorylation passes a certain threshold level leading to initial E2F1 release, 
which subsequently activates the CyclinE/CDK2 complex (Yao et al., 2008). That 
results in further Rb phosphorylation and more E2F1 release (Yao et al., 2008). 
Both pathways, the activation of the p53/p21 and the Chk2/Cdc25A, act to inhibit 
CDK activity. Therefore cells, which passed through the restriction point may 
already have sufficient Rb phosphorylation and therefore are less dependent on 
CDK inhibition. MYCN-high cells have short G1 phase (~4 hours), meaning that 
these cells are quickly passing through the restriction point. This explains why a 
higher proportion of MYCN-high cells accomplishes the G1/S transition compared 
to MYCN-low cells. The observation that the G2/M checkpoint is activated earlier 
than the G1/S checkpoint can be explained by the fact that cells use the fast 
Chk2/Cdc25 pathway to establish G2 arrest, Figure 9. 
An explanation for the second question, how MYCN delays cell cycle arrest, could 
be the upregulation of many critical cell cycle drivers such as E2F1, SKP2, CCNA2, 
CCNE1, CDK4, CCNB1, Cdc25A already under untreated conditions, Figure 15,18. 
Under DNA damage, it takes longer for MYCN-high cells to reduce the expression 
of these genes and as a consequence to establish the cell cycle arrest, Figure15. 
Additionally, MYCN can delay or suppress cell cycle arrest by the inhibition of p21 
(Bell et al., 2007). Interestingly, although the p53 protein was more strongly 
activated in MYCN-high cells, the p21 protein and RNA levels were almost equally 
activated under MYCN-low and MYCN-high conditions. This confirms the results of 
previous studies, which showed that MYCN, the same as MYCC, activates p53 but 
suppresses p21 expression (Bell et al., 2006; Chen et al., 2010; Reisman et al., 
1993; Roy et al., 1994; Seoane et al., 2002). It was suggested that MYCN 
represses p21 expression by increasing SKP2 and decreasing TP53INP1 
expression, (Bell et al., 2007). 
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4.1.2. MYCN sensitizes cells to apoptosis, suppresses cellular senescence 
and drives clonal regrowth of resister cells  
In consistence with observations made by other groups it was found that MYCN 
increases the proportion of cell death during treatment, Figure 9B,C (Bell et al., 
2006; Fulda et al., 2000; Gogolin et al., 2013). It has been reported that MYCN and 
MYCC upregulate p53 expression and switch p53 downstream effects from G1 
arrest to apoptosis, by increasing the transcription of the pro-apoptotic genes 
PUMA, BAX and PIG3 instead of CDKN1A (Chen et al., 2010; Seoane et al., 2002). 
Additionally, delayed cell cycle arrest activation and a high proportion of damaged 
cells passing through S and M phases early during treatment also contribute to the 
increased rate of cell death under MYCN-high conditions.  
Nevertheless, observations of cells after treatment showed that MYCN neither 
induces complete cell death in the whole population nor it allows cells to stay in the 
senescence stage, Figure 9,10,15. Here it was shown that a proportion of surviving 
cells was able to resume the cell cycle after treatment and a small fraction of these 
cells could divide properly and re-establish proliferation, Figure 9,15. The regrowth 
of MYCN-high cells was clonal, suggesting that only a very small number of cells 
could overcome chemotherapy. These data are in line with clinical observations for 
high-risk MYCN-amplified neuroblastomas, which are generally sensitive to the 
first-line therapy. However, the initial regression is frequently followed by the fast 
relapses and unfavorable disease progression (Canete et al., 2009; Kushner et al., 
2014). 
Of particular importance is the finding that ta second DOX treatment of resister cells 
resulted again in clonal regrowth with a comparable number of colonies as after the 
first treatment. This indicates that the therapy did not select for genetically distinct 
subpopulations that are resistant to DOX. Induction therapy for high-risk 
neuroblastoma usually consists of four to six cycles of chemotherapy (Kushner et 
al., 1994; Pradhan et al., 2006). The data of this study propose that after the first 
several rounds of chemotherapy the non-genetic heterogeneity rather than 
accumulated genetic mutations during treatment could be a reason for relapses.  
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4.1.3. Molecular expression profiles of resister cells are equal to untreated 
cells  
MYCN-low cells undergo drug-induced senescence and have active p53 and high 
p21 expression even two weeks after DOX treatment, Figure16. The p21 is a 
multifunctional protein that not only activates transient cell cycle checkpoints, but 
also inhibits apoptosis, regulates transcription, induces senescence-associated 
genes and suppresses mitosis-associated genes (Chang et al., 2000; Han et al., 
2002; Suzuki et al., 1999). The sustained upregulation of p21 is universally 
accepted to be primarily responsible inducing the senescence program (Chen et al., 
2006; Mirzayans et al., 2010; Roninson, 2003). Moreover, p21 is responsible for the 
apoptotic resistance of different cancer cell lines undergoing senescence after 
treatment with DOX (Crescenzi et al., 2008).  
Early after treatment MYCN-high cells had active p53 signaling and exhibited 
senescent morphology. Nevertheless, after regrowth the resister cells looked 
phenotypically similar to untreated cells and had low expression of p53 and p21 
proteins, Figure 16. The negative correlation between MYCN status and 
senescence was observed previously (Xue et al., 2007). It was described that at 
high doses of irradiation MYCN-amplified cell lines undergo apoptosis rather than 
cell cycle arrest, whereas MYCN single copy cells undergo senescence (Xue et al., 
2007). Thus, observations of this and previous studies suggest that MYCN 
suppresses cellular senescence.  
Global analysis of the transcriptome by RNA-Seq and the epigenome by Chip-Seq 
revealed that MYCN-high resister cells completely re-established the pre-treatment 
expression profiles, Figure 17,18,19. Analysis of molecular profiles together with 
observations made by live-cell imaging suggest that reduced activation of p53-p21 
signaling, the same as recovery of genome and epigenome in MYCN-high resister 
cells are a consequence of changes in the composition of the population over time. 
Early after treatment the culture was dominated by senescent cells, which later 
become diluted by the regrown resister cells that took over the population.  
In contrast, MYCN-low senescent cells maintained molecular profiles similar to that 
of cells during treatment: activated p53-signaling, suppression of cell cycle genes 
and, Figure 15,16,18. Senescence involves a tight interplay between the p53 and 
RB pathways (Chicas et al., 2012). The p53 acts as an inducer of various cell-cycle 
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inhibitory proteins, while RB acts as a repressor of E2F1 transcription (Courtois-
Cox et al., 2008). The analyzed histone modifications showed that senescent cells 
lose trimethylations of H3K4, H3K27 and H3K9, which correlated with the 
expression of histone-specific methyltransferases and demethylases. H3K4 
methylation is associated with actively transcribed genes; therefore the loss of this 
modification in senescent cells suggests that active histone demethylation might 
contribute to gene repression during senescence (Chicas et al., 2012). Decreased 
levels of histone H3K27me3 and its methyltransferase EZH2 are known markers for 
cellular senescence (Bracken et al., 2007; Fan et al., 2011). EZH2 depletion in 
melanoma cells inhibits cell proliferation, activates p21 and induces cellular 
senescence (Fan et al., 2011). The role of H3K9me3 on cellular senescence is 
controversial. Several studies reported the increase of H3K9me3 and its 
methyltransferase SUV39H1 in senescent cells (Di Micco et al., 2011; Dorr et al., 
2013). Whereas other studies showed that the decrease in global H3K9 
trimethylation together with downregulation of SUV39H1 leads to heterochromatin 
relaxation in pericentric satellite regions and thereby contributes to genomic 
instability and senescence (Czvitkovich et al., 2001; Peters et al., 2001; Sidler et 
al., 2014).  
 
4.1.4. Cellular regrowth is MYCN- and p21-dependent  
This work indicated that p21 is a critical factor for maintaining cellular senescence 
and preventing regrowth after treatment. Experiments on cells stably expressing 
shRNA against p21 revealed that activation of p53 without induction of p21 
expression leads to the suppression of senescence and induction of regrowth even 
in MYCN-low cells, Figure 20,21,22. It was found that absence of p21 during 
treatment significantly reduced the proportion of G1 arrested cells and increased 
percentage of cell death. As described previously, inhibition of p21 under DNA 
damage impedes activation of the G1/S checkpoint and leads to the induction of 
cell death (Crescenzi et al., 2008; Rousseau et al., 1999). The behavior of DOX 
treated MYCN-low cells with shRNA against p21 was very similar to those of 
MYCN-high cells with active p21. MYCN-low p21 knockdown cells were sensitized 
to death during and early after treatment, however this cell death was not complete 
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and a fraction of cells could form colonies and regrow. These results indicate that 
regrowth after chemotherapy can be explained by MYCN mediated suppression of 
p21.  
Switching the MYCN conditional expression after DOX treatment suggests that 
regulation of p21 is mediated by MYCN. During treatment both MYCN-low and 
MYCN-high cells arrest and have potential to undergo senescence. Lowering of the 
MYCN level after treatment is sufficient to maintain elevated p21 expression, push 
cells into senescence and reduce regrowth. Whereas inducing MYCN expression 
only after treatment leads to the reduction of p21 expression, escape from 
senescence, and the induction of proliferation. Interestingly, a small proportion of 
cells, which were MYCN-high during treatment and MYCN-low after treatment still 
could escape senescence and proliferate. This may indicate that either the 
switching of the MYCN status by doxycycline was not complete, or that these cells 
exhibit properties enabling cellular regrowth, which were influenced by MYCN 
already during treatment.  
In summary, experiments with p21 knockdown and with conditional regulation of 
MYCN expression after treatment provide a strong evidence that MYCN highly 
enhances the regrowth probability by repressing p21 expression after DOX 
treatment.  
 
4.1.5. Altered expression of FUCCI markers after DNA damage  
Under normal cycling conditions expression of FUCCI Cdt1 was found only during 
the G1 cell cycle phase, whereas FUCCI Geminin was expressed in G2 phase. 
Remarkably, altered expression of Cdt1 and Geminin was found in cells, which 
underwent cell cycle arrest after DNA damage. 20-24 hours after DOX addition 
cells showed deregulated expression of Cdt1 and Geminin fluorescence markers. 
Arrested cells exhibited high Cdt1 expression in G1 and G2 phases, while Geminin 
expression was completely lost in these cells, Figure 24, 25. Cells expressing high 
Cdt1 in G2 failed to process through mitosis. Similar loss of the Geminin FUCCI 
marker in G2 phase was observed after irradiation and establishment of the cell 
cycle in retinal epithelial cells (Krenning et al., 2014). 
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The expression of Cdt1 and Geminin is regulated by the sequential regulation of the 
E3 ubiquitin ligases APCCdh1 and SCFSkp2. Under normal cycling conditions the 
APCCdh1 ubiquitin ligase is active in the late M and G1 phases and targets Geminin 
for degradation, while the SCFSkp2 ubiquitin ligase is active only during S and G2 
phases and target Cdt1 for degradation (McGarry and Kirschner, 1998; Nishitani et 
al., 2004). Both Geminin and Ctd1 are highly expressed in G2, where Geminin 
binds and inhibits Cdt1 to prevent DNA re-replication (Klotz-Noack et al., 2012; 
Tada et al., 2001).  
In this study, accumulation of Cdt1 and loss of Geminin were correlated with low 
Skp2 expression in G2. Skp2 is a component of the E3 ubiquitin ligase SCFSkp2 
complex (Bornstein et al., 2003; Yu et al., 1998). In cycling cells, the levels of Skp2 
are low at late M and during G1, increase during G1/S transition and reach a 
maximum in G2 phase (Bashir et al., 2004; Wei et al., 2004). Skp1’s stability is also 
regulated by degradation in G1 phase through the APCCdh1 complex (Bashir et al., 
2004; Wei et al., 2004). Thus, high Cdt1 expression in G2 phase after DNA damage 
can be in part explained by the loss of its inhibitor Skp2, Figure 24B.   
A study on human fibroblasts and the colon cancer cell line showed that the 
APCcdh1 ligase activity can be prematurely activated in G2 as a part of a p53-p21-
dependent long-term response to DNA damage (Wiebusch and Hagemeier, 2010). 
Based on these data, loss of the Skp2 and Geminin in G2 phase after DNA damage 
can be explained by their degradation via APCcdh1 complex.  
The deregulation of FUCCI markers occurs 20-24 hours after DOX add whereas 
checkpoints are activated in the first 4 to 10 hours, therefore it was still possible to 
determine the phase of cell cycle arrest in single cells after DNA damage, Figure 
25. 
 
4.1.6. Resister cells arise from G1-arrested subpopulation 
Using extensive live-cell imaging, it was found that MYCN-high cells displayed 
great phenotypic variability after treatment washout. A fraction of cells died after 
treatment without entering mitosis, another fraction stayed arrested until the end of 
the observations, whereas a fraction of cells resumed the cell cycle within a few 
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days after treatment washout and entered mitosis. Most of the cells failed to 
correctly carry out the cytokinesis during mitosis, which resulted in undivided cells 
with fragmented nuclei and subsequent death of such cells, Figure 11. A minority of 
cells divided successfully into two phenotypical normal sister cells. These formed 
the basis for the new clonal population of resister cells.  
The fact that checkpoints are activated only several hours after DOX addition 
means that cells move from one cell cycle phase into the next before arrest. It was 
found that the progression of single cells through the cell cycle during treatment 
and the phase of their arrest are powerful predictors for the cell fates after 
treatment. 
Classification of the single cells into four groups according their phase of cell cycle 
immediately prior to treatment and at the end of the treatment indicated a specific 
subpopulation from where the resister cells arise. These were cells, which were at 
the M or early G1 phase at the time of DOX addition and stayed G1 arrested to the 
end of the treatment. In general, cells which transited through S or though M 
phases before arrest were more likely to die after treatment, had very low 
probability to re-enter the cell cycle and completely lacked the potential to regrow.  
The ability of more than 90% of MYCN-high cells arrested in G1 to resume the cell 
cycle suggests that the G1/S checkpoint is inefficiently maintained after treatment. 
These results can in part be explained by the twofold effect of MYCN the on cells 
cycle: activation of cell cycle genes and suppression of cell cycle inhibitor p21 (Bell 
et al., 2006; Tweddle et al., 2001). The observation that more than half of the cells 
which re-entered cell cycle after G1-arrest divided correctly and had potential to 
regrow points to the sufficient repair of DSBs in these cells. 
One possible explanation for the finding that G2-arrested cells lack the potential to 
regrow is the higher amount of DNA damage due to the limitation of the G1/S 
checkpoint during treatment (Deckbar et al., 2010). Since the G1/S checkpoint fails 
to prevent cells with DBSs from entering S phase within the first hours after 
treatment, such cells accumulate significantly elevated levels of unrepaired DSBs 
and chromosome breaks (Deckbar et al., 2010). Thus, high cell death and low cell 
cycle re-entry of G2-arrested cells could mean that these cells obtain irreparable 
damage and are eliminated from the population by p53-mediated apoptotic 
mechanisms (Petersen et al., 2010; Wahl et al., 1997). The limitations of the G2/S 
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checkpoint could be responsible for the strong death after treatment of cells 
transiting through M phase before arresting in G1 because cells which undergo 
mitosis with unrepaired DSBs very frequently lose their genetic material (Lobrich 
and Jeggo, 2007).   
One study on retinal epithelial cells also showed that after irradiation G1 arrested 
cells showed high cell cycle re-entry, while G2 cells mostly failed to enter mitosis 
and underwent senescence from their G2 arrested state (Krenning et al., 2014). It 
was shown that cell fate decisions after DNA damage in G2 are largely determined 
by activation the of p53 and APCCdh1 (Krenning et al., 2014). The irreversible 
withdrawal from cell cycle in G2 and establishment of senescence was explained 
by p21 and APCCdh1 mediated nuclear retention and degradation of Cyclin B1 
(Krenning et al., 2014). Other studies reported that p53-dependent downregulation 
of G2 cyclins, Cyclin B and Cyclin A, leads to permanent cell cycle arrest and that 
this is the first step in establishing senescence (d'Adda di Fagagna, 2008; Toettcher 
et al., 2009). This mechanism could explain the constant cell cycle arrest of MYCN-
low senescent cells, which had continuous low levels of Cyclins and an elevated 
level of p21 after treatment.  
 
4.1.7. G1-arrested resister cells have efficient DNA damage repair during 
treatment 
The earliest event of the DNA damage response is the phosphorylation of H2AX to 
yH2AX by the ATM, ATR and/or DNA/PK kinases (Harper and Elledge, 2007; 
Jackson and Bartek, 2009). yH2AX forms foci at DNA damage sites and these foci 
provide an indirect measure for DSBs in single cells. The ubiquitylation of yH2AX 
allows the accumulation of key repair factors like 53BP1 and BRCA1, which 
respectively determine the choice between NHEJ and HR repair pathways (Bergink 
and Jentsch, 2009; Callen et al., 2013; Lukas and Bartek, 2009; Mattiroli et al., 
2012; Zhu et al., 2015). NHEJ is active throughout the cell cycle, whereas HR is 
active only in S-G2 phases (Heyer et al., 2010; Lieber, 2010; Shrivastav et al., 
2008). Due to the finding that resister cells arise exclusively from G1-arrested 
subpopulation, this study was focusing on the analysis of DSBs repaired by NHEJ.   
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It was found that both MYCN-low and MYCN-high cells accumulate high amounts 
of DNA damage after DOX treatment but only MYCN-high cells recruit significantly 
more 53BP1 to the damage sites and activate NHEJ repair, Figure 30. Interestingly, 
the mean number of yH2AX foci at all analyzed time points was lower in MYCN-
high cells, and higher in MYCN-low cells, although all cells obtained the same 
amount of DNA damage. This may indicate that MYCN-high cells have higher 
repair efficiency. While MYCN-low cells had impaired NHEJ during treatment, 
therefore they were unable to repair their damage sites and through this 
accumulated a higher amount of yH2AX.  
53BP1 binding to DSBs is very complex and requires many determinants, including 
H4K20 methylation, RNF8-dependent degradation of competing H4K20me reads, 
H4K16 deacetylation, RNF168-mediated H2AK15 ubiquitylation and Ring1B/Bmil1-
reguated H2AX K118/119 ubiquitylation (Acs et al., 2011; Botuyan et al., 2006; 
Fradet-Turcotte et al., 2013; Hsiao and Mizzen, 2013; Tang et al., 2013; Zhu et al., 
2015). One possible explanation for the low 53BP1 foci formation in MYCN-low 
cells could be the low expression level of deubiquitinase USP7, which regulates the 
stability of RNF68 and Ring1B/Bmil1 (Ismail et al., 2010; Zhu et al., 2015). RNF68 
and Ring1B/Bmil1 are both ubiquitin ligases, which regulate 53BP1 recruitment to 
damaged sites (Bohgaki et al., 2013; Ismail et al., 2010). TET21N MYCN-low cells 
expressed lower basal level of USP7 (RNA-Seq data not shown) compared to 
MYCN-high cells. Thus, low USP7 expression could reduce 53BP1 recruitment and 
activation in MYCN-low cells. 
Analysis of 53BP1 foci dynamics in single cells by live-cell microscopy showed that 
G1 resister cells exhibit the most efficient DNA repair already during treatment, 
Figure 31. Only cells, which were in M/G1 at the beginning of treatment and 
arrested in G1 showed reduction in average foci numbers during treatment, 
indicating an early and efficient DNA repair via the NHEJ. Cells, which proceeded 
through S-phase during treatment and arrested in G2, had delayed repair induction, 
which resulted in subsequent cell death.  
Thus, the resister cells which accumulate in the G1 arrested subpopulation did not 
pass through S or M phase during treatment, possibly sustaining less DNA damage 
and showed enhanced activity of the NHEJ. Efficient DNA repair of G1-arrested 
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cells explains the high proportion of G1 cells re-entering cell cycle after DNA 
damage and as a consequence derivation of resister cells from this subpopulation.  
The efficiency of HR pathway was not investigated in this work; however, it is likely 
that this repair pathway plays a minor role in the DSBs repair after DOX. A study on 
colon cancer cells showed that NHEJ is the major contributor to the repair of DOX-
induced DNA damage (Schonn et al., 2011). Inhibition of HR did not affect the 
amount of DOX-induced damage and was not required for the repair of DSBs 
(Schonn et al., 2011). Interesting results were obtained by analysis of NHEJ and 
HR repair in live single cells using florescence reporters (Karanam et al., 2012). It 
was shown that NHEJ is a dominant repair pathway in G1 and in G2 even if both 
repair pathways are functional, while in S phase the activity of the NHEJ pathway 
was found to be low (Karanam et al., 2012). The HR is inactivated in G1, increases 
gradually in S and achieves maximum in the middle of S phase where the amount 
of DNA replication is highest and declines toward late S and G2 (Karanam et al., 
2012; Karanam et al., 2013). Furthermore, the it was shown that HR is slow in its 
activation reaches the maximum only 11h post DNA damage induction (Karanam et 
al., 2012). It is possible that cells transiting from G1 into S during the first several 
hours after treatment accumulate the highest amount of damage, which stays 
unrepaired because of the delayed activation of HR and downregulated NHEJ. A 
study in human fibroblasts demonstrated a double amount of yH2AX foci numbers 
in G2 compared to parallel cells in G1, which suggests that additional unrepaired 
DSBs arise during processing through S phase (Deckbar et al., 2010). 
DNA repair is usually suppressed during mitosis therefore mitotic cells continue to 
divide without repairing broken chromosomes (Zirkle and Bloom, 1953). 53BP1 
does not localize to sites of DNA damage during mitosis preventing sustaining 
NHEJ (Giunta et al., 2010; Nelson et al., 2009). Data from this work also indicate 
that cells transited from G2 into M never regrew and had delayed activation of 
NHEJ, probably only when they achieved G1 phase. Remarkably, it was found that 
if cells were already in M phases at the moment when treatment was applied then 
they usually arrested in G1, exhibited successful early repair and could regrow. 
Thus, these observations suggest that early activation of the NHEJ pathway is 
essential for efficient repair.  
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Collectively, these data indicate that delayed activation of cell cycle checkpoints 
during treatment results in the cellular accumulation of additional unrepaired DBSs, 
which probably can’t be completely repaired. While, early and efficient repair via the 
NHEJ of G1-arrested cells contributes to cell cycle re-entry and regrowth after 
chemotherapy.   
 
4.1.8. Tailored combined therapy that targets specific properties of resister 
cells successfully abolishes resisters.  
This work identified that resister cells are characterized by MYCN expression, G1 
arrest and efficient DNA repair. The specific features of resister cells were targeted 
to optimize the first-line therapy and to prevent regrowth after treatment. 
Synchronization of cells in G2 by CDK1 inhibitor prior to treatment resulted in the 
increased proportion of death during treatment and in the delayed regrowth of 
MYCN-high cells, Figure 32. It was not possible to completely abolish G1 
subpopulation and approximately 8 to 12 percent of the cells were always arrested 
in G1 during treatment. Live cells imaging revealed that exactly these G1 arrested 
cells could re-enter the cell cycle and generate colonies. The inhibition of CDK1 in 
cells overexpressing MYCC and MYCN is known to increase apoptosis through 
suppression of the apoptotic protein survivin (Chen et al., 2013; Goga et al., 2007).  
This work demonstrated that upon combined treatment with DOX plus CDK1 
inhibitor the cell death occurs mostly in G2 cells, whereas cells arrested in G1 
phase still have potential to regrow. Hence, already a single resister cell is sufficient 
to generate a colony and initiate tumor relapse. Since even in vitro it is impossible 
to achieve a complete synchronization, this strategy is unlikely to be effective in 
clinical applications. 
Interesting results were achieved by synchronizing of cells in G1 using CDK4 
inhibitor. One could expect that accumulation of the population in G1 should enrich 
number of regrowing cells, however, after combined treatment with DOX plus CDK4 
inhibitor only a reduced regrowth of MYCN-high cells was observed, Figure 33. 
CDK4 is usually unregulated by MYCN, which leads to the activation of Rb 
signaling and represents the mechanism by which MYCN cells evade G1 arrest 
(Westermann et al., 2008). Therefore the inhibition of CDK4 restores the G1/S 
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arrest in MYCN-amplified neuroblastoma cell lines (Gogolin et al., 2013; Rihani et 
al., 2015). The reduced regrowth rate of cells enriched in G1 may indicate that 
inhibition of CDK4 suppresses important players responsible for G1/S transition 
after treatment and that CDK4 inhibition can delay but not abolish resistance. Thus, 
DNA repair alone is not sufficient to initiate regrowth, and the synergy between 
activation of cell cycle proteins and efficient DNA repair is responsible for 
chemoresistance.  
Targeting another property of resister cells, the efficient DNA damage repair 
resulted in the eradication of resister cells. Several inhibitors against proteins 
involved in DNA damage response in combination with DOX treatment were tested. 
In general all of the tested inhibitors delayed regrowth but only combined treatment 
of DOX plus ATMi completely abolished resistance in all analyzed cell lines, Figure 
34, 36.  
In response to DSBs, ATM initiates a cascade of phosphorylation events, which 
activate cell cycle arrest by p53 signaling and promote DNA repair by both HR and 
NHEJ (Cortez et al., 1999; Riballo et al., 2004; Shiloh, 2006). Previous studies with 
ATM inhibitors showed significant chemo- and radiosensitization, in in vivo and in 
virto models of colon cancer and glioma, with the absence of toxicity (Batey et al., 
2013; Vecchio et al., 2014; Vecchio et al., 2015). It was shown that ATM inhibition 
sensitizes some glioma cell lines to ionizing irradiation by pushing cells into 
proliferation (Raso et al., 2012). This study showed similar effects, combined 
treatment with DOX plus ATM inhibitor prevented ATM phosphorylation and 
activation of p53 signaling, Figure 37. This resulted in the failure of G1/S checkpoint 
with accumulation of MYCN-high cells in G2, failed NHEJ repair activation, and 
subsequent cell death with eradication of resister cells, Figure 38. Interestingly, the 
MYCN-low cells just very slightly increased the number of cell death and 
permanently stayed arrested after combined therapy. Thus the almost complete 
death of MYCN-high cells compared with the low death rate of MYCN-low cells 
suggests that in context with combined therapy the MYCN-promoted apoptosis is 
an important feature that helps to abolish resistance.  
The success of combined treatment with DOX and ATM can be explained by 
targeting the specific features of resister cells. This include the reduction of G1 
arrested cells and the increase of the number of cells transiting into S phase during 
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treatment, inhibition of DSB repair, and activation of MYCN-mediated apoptosis in 
unrepaired cells.  
 
4.1.9. Conclusions 
The present study provides the basis for the understanding of the mechanisms 
through which oncoprotein MYCN sensitizes cells to death during chemotherapy 
and promotes cellular regrowth thereafter, Figure 39. 
MYCN shortens cell cycle phases and accelerates proliferation by enhancing the 
expression of cell cycle genes under standard in vitro growth conditions. This 
results in delayed activation of cell cycle arrest and increases the proportion of cells 
transiting through G1/S and G2/M upon chemotherapy. High proportion of cells 
entering S and M phases during DNA damage is one of the mechanisms how 
MYCN sensitizes cells to death. Another mechanism is that MYCN switches the 
p53 function in favor of apoptosis rather than cell cycle arrest and senescence by 
activation of 53-induced cell death and suppression of cell cycle inhibitor p21. 
However, MYCN-induced cell death is not complete and MYCN also drives the 
clonal regrowth of a small fraction of surviving resister cells after therapy. The 
closer characterization revealed that resister cells arise exclusively from the G1-
arrested subpopulation. MYCN-dependent regrowth can be explained by efficient 
DNA repair in G1 and activation of cell cycle genes after treatment, both promoted 
by MYCN.  
Suppression of DNA DSBs repair by inhibition of ATM during DNA damage reduces 
the proportion of G1-arrested cells and prevents DNA repair, leading to complete 
eradication of resister cells. This work shows that targeting specific features of 
resister cells may help to improve first-line therapy and to avoid resistance. 
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Figure 39. Summary of cellular outcomes after chemotherapy. 
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6. List of abbreviations 
aa   amino acids 
b   base 
bp    base pair 
BSA    bovine serum albumin 
cDNA   complementary DNA 
ChIP    chromatin immunoprecipitation 
ChIP   chip chromatin immunoprecipitation on chip 
cm    centimeter 
Cp    crossing point 
d    day(s) 
DAPI    4,6-Diamino-2-phenylindol 
DNA    desoxyribonucleic acid 
DNase   desoxyribonuclease 
dNTP    2'-deoxyribonucleoside 5’-triphosphate 
DSBs   double strand breaks 
DMSO   dimethylsulfoxid 
DOX    doxorubicin 
EDTA   ethylendiamintetraacetic acid, Na-salt 
EdU   5-ethynyl-2’-deoxyuridine 
et al.    et alii (and other) 
EtOH    ethanol 
FACS   fluorescence activated cell sorting 
FBS    fetal Bovine serum 
FUCCI  Fluorescent Ubiquitination-based Cell Cycle Indicator  
g    gram 
xG   force of gravity, relative centrifugal force (RCF) 
GFP   green fluorescence protein 
H3K4me3   trimethylation of histone 3 at lysine residue 4 
H3K27me3   trimethylation of histone 3 at lysine residue 27 
H3K36me3   trimethylation of histone 3 at lysine residue 36 
h    hour(s) 
I   inhihbitor 
i.e.    is est ( that is) 
IgG   immunoglobulin G 
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M    molar 
m    milli 
mA    millampere 
mAbmin   minute(s) 
mRNA   messenger RNA 
µ    micro 
n    nano 
PAGE   polyacrylamide gel electrophoreses 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PFA   paraformaldehyde 
PVDF   polyvinylidenfluorid 
qRT-PCR   quantitative Real-time RT-PCR 
RNA    ribonucleic acid 
RNase   ribonuclease 
RPMI1640   Rosvell Park Memorial Institute, medium formulation 1640 
RT    room temperature 
RT-PCR   reverse Transcription reaction followed by PCR 
SA-β-Gal  Senescence-associated β-Galactosidase 
sec    second(s) 
SEM   standard error of the mean 
SD   standard deviation 
SDS    sodiumdodecylsulfat 
Tet    tetracycline 
WB    western blotting 
 
 
 
 
 
 
 	  
